[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 321
1. Clark AJ, Lu DC, Richardson RM, Tihan T, Parsa AT, Chou D, Barbaro NM, Kunwar S, Weinstein PR, Lawton MT, Berger MS, McDermott MW: Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg; 2010 Jul;74(1):200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Spinal hemangioblastomas (SH) are definitively treated by en bloc microsurgical resection.
  • Although benign, their highly vascular nature makes resection challenging.
  • A major difficulty involves intraoperative differentiation of vessels supplying the tumor from those supplying the spinal cord.
  • Temporary arterial occlusion (TAO) by aneurysm clip placement with concurrent neuromonitoring was used at the tumor edge to differentiate arteries supplying the tumor from those supplying the healthy spinal cord.
  • Arteries were assumed to not supply important regions of the cord and divided at the tumor surface if there was no change in evoked potentials after 4 minutes of occlusion.
  • CONCLUSIONS: Temporary arterial occlusion with neuromonitoring is a safe, effective, and simple method of differentiating arteries supplying the tumor only from those that supply the functionally normal spinal cord in the operative management of difficult SH.
  • [MeSH-major] Evoked Potentials, Motor / physiology. Evoked Potentials, Somatosensory / physiology. Hemangioblastoma / blood supply. Hemangioblastoma / surgery. Intraoperative Complications / physiopathology. Intraoperative Complications / prevention & control. Microsurgery / methods. Monitoring, Intraoperative. Spinal Cord / blood supply. Spinal Cord Ischemia / physiopathology. Spinal Cord Ischemia / prevention & control. Spinal Cord Neoplasms / blood supply. Spinal Cord Neoplasms / surgery. Surgical Instruments. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adult. Aged. Arteries / pathology. Arteries / surgery. Cervical Vertebrae / blood supply. Cervical Vertebrae / pathology. Cervical Vertebrae / surgery. Craniotomy / methods. Female. Follow-Up Studies. Humans. Laminectomy / methods. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [CommentIn] World Neurosurg. 2010 Jul;74(1):116-7 [21299999.001]
  • (PMID = 21300014.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, Knight B: Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol; 2005 Sep;98(3):409-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
  • OBJECTIVES: The obligate intracellular bacterium Chlamydia trachomatis is frequently found in association with benign proliferative, pre-neoplastic and malignant changes in cervical epithelium.
  • The present study addresses the possible role of C. trachomatis infection of the uterine cervix in modulating human cancer gene expression.
  • Forty specimens of cervix dissected from the transformation zone had previously tested negative for HPV and positive for C. trachomatis by standard DNA PCR (20).
  • The cultures showed a 2-fold decrease in the expression of the gene coding for the tumor suppressor caveolin-1, and increased expression of the oncogene C-myc, a promoter of cervical carcinogenesis.
  • In tissues from the Chlamydia-infected cervical transformation zone, real-time RT-PCR demonstrated a highly significant average 4.7-fold reduction of caveolin-1 mRNA (P < or = 0.0001) and an average 2.1-fold increase in C-myc (P < 0.05).
  • CONCLUSIONS: Human ITFgamma-treated fibroblasts as well as non-neoplastic cervical tissues responded to C. trachomatis with a strong down-regulation of caveolin-1 mRNA and a light up-regulation of C-myc mRNA.
  • This study reveals possible mechanisms by which C. trachomatis infection may contribute to neoplastic changes in the transformation of uterine cervix.
  • [MeSH-major] Caveolins / genetics. Cell Transformation, Neoplastic / genetics. Cervix Uteri / microbiology. Chlamydia trachomatis / physiology. Genes, Tumor Suppressor / physiology. Genes, myc / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / microbiology


3. Gerszten PC, Novotny J Jr, Quader M, Dewald VC, Flickinger JC: Prospective evaluation of a dedicated spine radiosurgery program using the Elekta Synergy S system. J Neurosurg; 2010 Dec;113 Suppl:236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stratifying the lesion by location, there were 28 cervical, 69 thoracic, 48 lumbar, and 21 sacral lesions.
  • The most common benign tumors (30 cases total) included 10 schwannomas, 5 neurofibromas, and 5 meningiomas.
  • RESULTS: The prescribed dose to the gross tumor volume, delivered in a single fraction, ranged from 12 to 20 Gy (mean 16 Gy) in this cohort.
  • The gross tumor volumes ranged from 1.2 to 491.7 cm(3) (mean 39.2 cm(3)).
  • [MeSH-major] Radiosurgery / instrumentation. Spinal Neoplasms / surgery. Spine / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121807.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kim TY, Hong SJ, Kim JM, Kim WG, Gong G, Ryu JS, Kim WB, Yun SC, Shong YK: Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer; 2008;8:296
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrence was observed in 8 of 166 patients (0.5%) treated with total or near-total thyroidectomy; gender (P = 0.02) and presence of lateral cervical node metastases at initial surgery (P = 0.01) were associated with recurrence.
  • Multivariate Cox-regression analysis showed that gender and cervical lymph node metastasis were significant variables CONCLUSION: PTMC showed very diverse disease extent and could not be regarded as indolent, relatively benign disease based on the primary tumor size.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Neoplasm Recurrence, Local / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Factors. Thyroglobulin. Thyrotropin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2001;31(9):763-7 [11686552.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] Thyroid. 2003 Apr;13(4):381-7 [12804106.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):31-40 [12833452.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Sep;15(6):329-36 [14524486.001]
  • [Cites] World J Surg. 2004 May;28(5):498-501 [15085396.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Surgery. 1992 Dec;112(6):1139-46; discussion 1146-7 [1455316.001]
  • [Cites] World J Surg. 1998 Jan;22(1):99-102 [9465769.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):553-9 [9690549.001]
  • [Cites] Endocr J. 1999 Feb;46(1):209-16 [10426589.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1115-21 [15490053.001]
  • [Cites] World J Surg. 2006 Jan;30(1):91-9 [16369721.001]
  • [Cites] Yonsei Med J. 2000 Feb;41(1):22-8 [10731915.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] Surg Today. 2006;36(11):947-53 [17072713.001]
  • [Cites] Endocr J. 2006 Oct;53(5):627-32 [16896263.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1144-8 [16872798.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Mar;3(3):240-8 [17315032.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):399-407 [12616125.001]
  • (PMID = 18851763.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  • [Other-IDs] NLM/ PMC2576338
  •  go-up   go-down


5. Nguyen NT, Hinojosa MW, Smith BR, Chang KJ, Gray J, Hoyt D: Minimally invasive esophagectomy: lessons learned from 104 operations. Ann Surg; 2008 Dec;248(6):1081-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To review the outcomes of 104 consecutive minimally invasive esophagectomy (MIE) procedures for the treatment of benign and malignant esophageal disease.
  • RESULTS: Indications for surgery were esophageal cancer (n = 80), Barrett esophagus with high-grade dysplasia (n = 6), recalcitrant stricture (n = 8), gastrointestinal stromal tumor (n = 3), and gastric cardia cancer (n = 7).
  • Surgical approaches included thoracoscopic/laparoscopic esophagectomy with a cervical anastomosis (n = 47), minimally invasive Ivor Lewis esophagectomy (n = 51), laparoscopic hand-assisted blunt transhiatal esophagectomy (n = 5), and laparoscopic proximal gastrectomy (n = 1).
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods
  • [MeSH-minor] Aged. Barrett Esophagus / surgery. Cardia. Female. Hospital Mortality. Humans. Laparoscopy. Length of Stay. Male. Middle Aged. Postoperative Care. Retrospective Studies. Stomach Neoplasms / surgery. Surgical Stapling. Thoracoscopy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2010 Jan;251(1):178-9; author reply 179 [19935401.001]
  • (PMID = 19092354.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Boriani S, Bandiera S, Donthineni R, Amendola L, Cappuccio M, De Iure F, Gasbarrini A: Morbidity of en bloc resections in the spine. Eur Spine J; 2010 Feb;19(2):231-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity of en bloc resections in the spine.
  • This is particularly true of en bloc resections, the most technically demanding procedures.
  • A retrospective review of prospective data from a large series of en bloc resections may help to identify risk factors, and therefore to reduce the rate of complications and to improve outcome.
  • A retrospective study of 1,035 patients affected by spine tumors-treated from 1990 to 2007 by the same team-identified 134 patients (53.0% males, age 44 +/- 18 years) who had undergone en bloc resection for primary tumors (90) and bone metastases (44).
  • The study was set up to correlate diagnosis, staging and treatment with the outcome.
  • Oncological and functional results were recorded for all patients at periodic, diagnosis-related controls, until death or the latest follow-up examination (from 0 to 211 months, median 47 months, 25th-75th percentile 22-85 months).
  • Of the 35 patients with a recurrent or contaminated tumor, 16 (45.7%) suffered at least one complication; by contrast, complications arose in 31 (31.3%) of the 99 patients who had had no previous treatment and who underwent the whole of their treatment in the same center (P = 0.125).
  • Re-operations were mostly due to tumor recurrences, but also to hardware failures, wound dehiscence, hematomas and aortic dissection.
  • En bloc resection is able to improve the prognosis of aggressive benign and low-grade malignant tumors in the spine; however, complications are not rare and possibly fatal.
  • [MeSH-major] Neurosurgical Procedures / methods. Neurosurgical Procedures / mortality. Postoperative Complications / mortality. Spinal Neoplasms / pathology. Spinal Neoplasms / surgery. Spine / surgery
  • [MeSH-minor] Adult. Aged. Aortic Rupture / mortality. Equipment Failure. Female. Humans. Male. Middle Aged. Mortality. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Outcome Assessment (Health Care). Radiotherapy / adverse effects. Reoperation / mortality. Retrospective Studies. Surgical Wound Dehiscence / mortality. Surgical Wound Infection / mortality. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2000 Apr 1;25(7):804-12 [10751291.001]
  • [Cites] Spine (Phila Pa 1976). 2012 Jan 1;37(1):E37-45 [22179322.001]
  • [Cites] Orthopedics. 2002 Jan;25(1):37-42 [11811240.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Sep 15;28(18):E368-72 [14501938.001]
  • [Cites] J Spinal Disord Tech. 2004 Aug;17(4):297-300 [15280758.001]
  • [Cites] Acta Orthop Scand. 1984 Oct;55(5):491-500 [6507069.001]
  • [Cites] Clin Orthop Relat Res. 1989 Aug;(245):72-82 [2752635.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Jul 15;20(14):1592-9 [7570174.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jun;78(6):839-47 [8666601.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Aug 15;21(16):1927-31 [8875727.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 1;22(3):324-33 [9051895.001]
  • [Cites] Spine (Phila Pa 1976). 1997 May 1;22(9):1036-44 [9152458.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Aug 1;22(15):1773-82; discussion 1783 [9259790.001]
  • [Cites] Spine (Phila Pa 1976). 1998 Mar 15;23(6):726-32; discussion 732-3 [9549795.001]
  • [Cites] Chir Organi Mov. 1998 Jan-Jun;83(1-2):53-64 [9718815.001]
  • [Cites] Chir Organi Mov. 1998 Jan-Jun;83(1-2):65-72 [9718816.001]
  • [Cites] Clin Orthop Relat Res. 1998 Sep;(354):189-94 [9755779.001]
  • [Cites] Eur Spine J. 1998;7(6):438-44 [9883951.001]
  • [Cites] Spine (Phila Pa 1976). 1999 Sep 15;24(18):1943-51 [10515021.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Aug 15;30(16):1899-908 [16103863.001]
  • [Cites] Spine (Phila Pa 1976). 2006 Feb 15;31(4):493-503 [16481964.001]
  • [Cites] Spine (Phila Pa 1976). 2008 Sep 15;33(20):2243-7 [18794768.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1 Suppl):25-37 [11147865.001]
  • (PMID = 19690899.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899819
  •  go-up   go-down


7. Rubaltelli L, Stramare R, Tregnaghi A, Scagliori E, Cecchelero E, Mannucci M, Gallinaro E, Beltrame V: The role of sonoelastography in the differential diagnosis of neck nodules. J Ultrasound; 2009 Sep;12(3):93-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of sonoelastography in the differential diagnosis of neck nodules.
  • In the study of cervical lymph nodes, the results were less impressive (sensitivity 75%, specificity 80%, accuracy 77%, PPV 80%, NPV 70%), but the information obtained with this technique can in our opinion be a useful adjunct to sonographic findings.
  • Indeed, in 5 lymph nodes with sonographic features consistent with malignancy, sonoelastography revealed diffuse elasticity that was indicative of benign disease, which was confirmed by pathological studies.
  • Sonoelastography is rapid and simple to perform, and it appears to be a potentially useful tool for the differential diagnosis of neck nodules.
  • Our experience with these lesions indicates that diffuse elasticity is strongly correlated with benign disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] J Ultrasound Med. 2004 Nov;23(11):1455-64 [15498910.001]
  • [Cites] Radiology. 1991 Dec;181(3):683-7 [1947082.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):654-7 [1463118.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Radiol Med. 2005 Jul-Aug;110(1-2):69-76 [16163141.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Radiology. 2006 May;239(2):341-50 [16484352.001]
  • [Cites] Ultraschall Med. 2006 Dec;27(6):535-42 [17160759.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Gastrointest Endosc. 2007 Jun;65(7):971-8 [17531630.001]
  • [Cites] J Ultrasound Med. 2007 Jun;26(6):797-805 [17526611.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):291-300 [17643702.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2917-22 [17535993.001]
  • [Cites] Ultraschall Med. 2009 Apr;30(2):175-9 [18496776.001]
  • [Cites] J Ultrasound. 2008 Jun;11(2):47-54 [23396751.001]
  • (PMID = 23396686.001).
  • [ISSN] 1971-3495
  • [Journal-full-title] Journal of ultrasound
  • [ISO-abbreviation] J Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3552973
  • [Keywords] NOTNLM ; Technology assessment / Thyroid / Tumor
  •  go-up   go-down


8. Parekh DJ, Lin WC, Herrell SD: Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality. J Urol; 2005 Nov;174(5):1754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality.
  • PURPOSE: Promising results of optical signals have been reported in the literature for the diagnosis of Barrett's esophagus, oral cavity lesions, brain tumor margins, cervical intraepithelial neoplasia, skin cancer and bladder cancer.
  • The potential usefulness of these techniques in renal tissues and neoplasms has not been described to date.
  • This initial study examined the feasibility of using fluorescence and diffuse reflectance spectroscopy to differentiate between malignant and benign renal tissues.
  • Pathologically confirmed benign and malignant renal samples were obtained from nephrectomy specimens from patients undergoing radical nephrectomy.
  • Fluorescence and diffuse reflectance spectra were measured from benign and malignant renal tissues.
  • RESULTS: All renal tissues, malignant or benign, contain 2 primary emission peaks-a strong one at approximately 285 nm excitation, approximately 340 nm emission (Peak A), and a weak one at approximately 340 nm excitation, approximately 460 nm emission (Peak B).
  • The intensity of Peak B from benign tissues tends to be greater than that from malignant renal tissues.
  • Empirical discrimination algorithms developed based on selected fluorescence and diffuse reflectance spectral characteristics yields accurate differentiation between benign and malignant renal tissues.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Precancerous Conditions / pathology. Spectrometry, Fluorescence
  • [MeSH-minor] Case-Control Studies. Diagnosis, Differential. Female. Humans. Kidney / pathology. Male. Reference Values. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Nov;174(5):1723-4 [16217270.001]
  • (PMID = 16217277.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Shamji MF, Benoit BG, Perry A, Jansen GH: Giant cell ependymoma of the thoracic spine: pathology case report. Neurosurgery; 2009 Mar;64(3):E566-7; discussion E567
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION AND IMPORTANCE: Spinal ependymomas are slow-growing lesions that comprise the majority of primary spinal cord neoplasms.
  • When surgery is indicated, the extent of tumor removal is most prognostic for long-term survival.
  • Unusual histological subtypes can make intraoperative diagnosis spurious, possibly altering the surgical approach from gross total resection for ependymomas to debulking for high-grade astrocytomas.
  • CONCLUSION: We present this first reported case of thoracic spine giant cell ependymoma alongside scant literature yielding 1 case in the cervical spine and 2 cases at the filum terminale.
  • Those cases had benign courses, whereas ours demonstrates a high degree of proliferation, making the malignant potential difficult to assess.
  • [MeSH-major] Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Ependymoma / pathology. Ependymoma / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / surgery. Thoracic Vertebrae / pathology. Thoracic Vertebrae / surgery

  • Genetic Alliance. consumer health - Ependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240583.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • Of 30 tumors of the uterine corpus, 17 were stage IA, 11 stage IB, 1 stage IC, and 1 stage IIIC.
  • Four cervical tumors were stage IB.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Most uterine tumors were polypoid masses ranging from 1 to 20 cm (mean: 6.5 cm).
  • Fourteen of 30 uterine tumors (47%) had myometrial invasion that was minimal in 5, involved one-third of the myometrial thickness in 7, and more than 50% in 2.
  • Of 4 cervical tumors, 2 were endocervical polyps, 1 invaded one-third of the cervical wall, and the other invaded its full thickness.
  • Six developed metastases and 5 of them died of tumor.
  • Four had adenosarcomas with sarcomatous overgrowth; however, the other 2 patients had typical low-grade adenosarcomas of the uterine corpus and cervix, respectively, exhibiting only mild nuclear atypia of the stromal component and </=2 mitotic figures/10 high power fields.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Stewart CJ, Little L: Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. Pathology; 2010 Apr;42(3):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-two cervical biopsy specimens including normal endocervical epithelium, tubo-endometrioid metaplasia, adenocarcinoma in situ, stratified mucin producing intraepithelial lesions (SMILE), and invasive adenocarcinomas were stained immunohistochemically for vimentin and for p16 protein, Ki-67 and bcl-2.
  • Twelve cases also included areas of high grade cervical intraepithelial neoplasia (CIN).
  • Usually adenocarcinoma in situ was completely negative and therefore vimentin staining sharply distinguished the benign and neoplastic epithelial elements.
  • Most invasive adenocarcinomas were not stained but focal vimentin immunoreactivity was observed in 7/18 cases, and was restricted to small glands and infiltrating cell clusters at the deep (advancing) tumour margin.
  • Therefore vimentin is a useful additional diagnostic marker in the assessment of problematic cervical glandular lesions.
  • The localised re-expression of vimentin at the deep margin of some endocervical adenocarcinomas may be relevant to the process of tumour progression and invasion in these cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350213.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  •  go-up   go-down


13. Missaoui N, Trabelsi A, Hmissa S, Fontanière B, Yacoubi MT, Mokni M, Korbi S, Frappart L: p16INK4A overexpression in precancerous and cancerous lesions of the uterine cervix in Tunisian women. Pathol Res Pract; 2010 Aug 15;206(8):550-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4A overexpression in precancerous and cancerous lesions of the uterine cervix in Tunisian women.
  • Uterine cervix cancer is an important public health problem in developing countries.
  • The study was performed to evaluate the usefulness of p16(INK4A) overexpression as a surrogate marker for uterine cervix precancerous lesions and high-risk human papillomavirus (HPV) infection.
  • We conducted a retrospective study of 87 uterine cervix specimens, including 7 normal tissue samples, 17 benign lesions, 34 precancerous lesions, 22 invasive squamous cell carcinomas (SCC), and 7 adenocarcinomas.
  • No immunoreactivity for p16(INK4A) was detected in normal tissue or benign lesions. p16(INK4A) immunoreactivity was focal in CIN1, whereas strong and diffuse immunoreactivity for p16(INK4A) was uniformly observed in both the nucleus and the cytoplasm of all CIN2 and 3, as well as in those of invasive SCC and adenocarcinomas.
  • p16(INK4A) overexpression is a useful additional marker for the interpretation of problematic uterine cervical lesions and can help to reduce the variability during evaluation of suspicious biopsies of the uterine cervix.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Papillomavirus Infections / complications. Polymerase Chain Reaction. Retrospective Studies. Tunisia


14. Zheng ZM, Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci; 2006 Sep 01;11:2286-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillomaviruses are a group of small non-enveloped DNA tumor viruses whose infection usually causes benign epithelial lesions (warts).
  • Certain types of HPVs, such as HPV-16, HPV-18, and HPV-31, have been recognized as causative agents of cervical cancer and anal cancer and their infections, which arise via sexual transmission, are associated with more than 95% of cervical cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1986 Sep;5(9):2285-92 [3023067.001]
  • [Cites] J Virol. 1987 Jan;61(1):134-42 [3023691.001]
  • [Cites] Nature. 1987 Jan 1-7;325(6099):70-3 [3025749.001]
  • [Cites] Cell. 1987 Jul 3;50(1):69-78 [3036366.001]
  • [Cites] EMBO J. 1988 Feb;7(2):525-31 [2835231.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3780-6 [2837324.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(16):5864-8 [2842752.001]
  • [Cites] J Virol. 1989 Mar;63(3):1441-7 [2536845.001]
  • [Cites] J Virol. 1989 Apr;63(4):1743-55 [2538655.001]
  • [Cites] J Virol. 1989 Aug;63(8):3529-34 [2545923.001]
  • [Cites] Virology. 1989 Sep;172(1):331-40 [2549716.001]
  • [Cites] J Virol. 1990 Apr;64(4):1825-9 [2157064.001]
  • [Cites] J Virol. 1990 Jun;64(6):2849-59 [2159546.001]
  • [Cites] Biochim Biophys Acta. 1990 Jun 1;1032(1):19-37 [2163676.001]
  • [Cites] Virology. 1990 Sep;178(1):254-62 [2167553.001]
  • [Cites] J Virol. 1991 Apr;65(4):2093-7 [1848319.001]
  • [Cites] J Virol. 1991 Sep;65(9):4860-6 [1651408.001]
  • [Cites] J Virol. 1991 Nov;65(11):5806-12 [1717710.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):356-64 [1310488.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] J Virol. 1992 Oct;66(10):6070-80 [1326657.001]
  • [Cites] Virology. 1992 Dec;191(2):953-9 [1333130.001]
  • [Cites] Biochem Mol Biol Int. 1998 Aug;45(5):1005-9 [9739465.001]
  • [Cites] Nucleic Acids Res. 1998 Dec 1;26(23):5237-42 [9826743.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):113-25 [10594014.001]
  • [Cites] J Virol. 2000 Feb;74(3):1178-86 [10627528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4677-82 [10781073.001]
  • [Cites] J Virol. 2000 Jul;74(13):5902-10 [10846071.001]
  • [Cites] J Virol. 2000 Aug;74(16):7284-97 [10906182.001]
  • [Cites] J Virol. 2000 Nov;74(22):10612-22 [11044105.001]
  • [Cites] J Virol. 2001 May;75(9):4139-49 [11287563.001]
  • [Cites] J Virol. 2001 Sep;75(17):8147-57 [11483760.001]
  • [Cites] J Virol. 2001 Oct;75(19):9201-9 [11533183.001]
  • [Cites] J Virol. 2002 Mar;76(5):2263-73 [11836404.001]
  • [Cites] J Virol. 2002 Mar;76(6):2739-52 [11861841.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 15;30(8):1842-50 [11937639.001]
  • [Cites] J Virol. 2002 Jun;76(12):5993-6003 [12021332.001]
  • [Cites] J Virol. 2002 Jul;76(14):7040-8 [12072504.001]
  • [Cites] J Mol Biol. 2002 May 17;318(5):1189-206 [12083511.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6041-8 [12203116.001]
  • [Cites] Virology. 2002 Sep 15;301(1):43-52 [12359445.001]
  • [Cites] J Virol. 2002 Nov;76(22):11291-300 [12388689.001]
  • [Cites] Genome Biol. 2002 Oct 23;3(11):reviews0008 [12429065.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):765-77 [15868908.001]
  • [Cites] Curr Opin Cell Biol. 2005 Jun;17(3):257-61 [15901494.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):143-51 [15905729.001]
  • [Cites] Biochem Soc Trans. 2005 Jun;33(Pt 3):443-6 [15916537.001]
  • [Cites] J Virol. 2005 Jul;79(14):9254-69 [15994820.001]
  • [Cites] J Virol. 2005 Sep;79(18):12002-15 [16140776.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6544-9 [16166431.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8643-55 [16166644.001]
  • [Cites] Gene Ther. 2005 Oct;12(20):1477-85 [16121205.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9595-607 [16227608.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2094-104 [16369495.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):371-8 [15372045.001]
  • [Cites] J Virol. 2004 Oct;78(20):10888-905 [15452209.001]
  • [Cites] J Virol. 2004 Oct;78(20):11172-86 [15452237.001]
  • [Cites] Eur J Biochem. 1980 Aug;109(2):457-61 [6250842.001]
  • [Cites] Nature. 1982 Oct 7;299(5883):529-34 [6289124.001]
  • [Cites] Virology. 1983 Apr 30;126(2):493-504 [6305000.001]
  • [Cites] EMBO J. 1982;1(2):231-6 [6325156.001]
  • [Cites] Nucleic Acids Res. 1984 Dec 11;12(23):8847-60 [6096809.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] J Virol. 2003 Feb;77(3):2021-8 [12525636.001]
  • [Cites] J Virol. 2003 Feb;77(3):2105-15 [12525645.001]
  • [Cites] Antivir Ther. 2002 Dec;7(4):219-37 [12553476.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Virol. 2003 Apr;77(8):4928-37 [12663798.001]
  • [Cites] J Virol. 2003 May;77(9):5167-77 [12692219.001]
  • [Cites] J Virol. 2003 May;77(10):6066-9 [12719599.001]
  • [Cites] J Virol. 2003 Jun;77(11):6227-34 [12743279.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):111-6 [12807954.001]
  • [Cites] Virology. 2003 Jun 20;311(1):105-14 [12832208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8264-9 [12826613.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5938-45 [12955072.001]
  • [Cites] J Virol. 2003 Oct;77(19):10186-201 [12970404.001]
  • [Cites] J Virol. 2003 Oct;77(19):10213-26 [12970406.001]
  • [Cites] J Virol. 2003 Nov;77(21):11674-84 [14557653.001]
  • [Cites] J Gen Virol. 2003 Nov;84(Pt 11):2909-20 [14573795.001]
  • [Cites] J Virol. 2003 Dec;77(23):12450-9 [14610169.001]
  • [Cites] Virus Res. 2003 Dec;98(2):95-104 [14659556.001]
  • [Cites] J Virol. 2004 Jan;78(2):612-29 [14694093.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):616-26 [14749727.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4680-4 [3014503.001]
  • [Cites] J Virol. 2004 Mar;78(5):2609-14 [14963167.001]
  • [Cites] Nat Rev Microbiol. 2004 Apr;2(4):343-7 [15031733.001]
  • [Cites] RNA. 2004 Apr;10(4):565-73 [15037765.001]
  • [Cites] J Mol Biol. 2004 Apr 9;337(5):1091-108 [15046980.001]
  • [Cites] J Biomed Sci. 2004 May-Jun;11(3):278-94 [15067211.001]
  • [Cites] J Gen Virol. 2004 Jun;85(Pt 6):1433-44 [15166426.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Virology. 2004 Jul 1;324(2):483-92 [15207633.001]
  • [Cites] Virology. 2004 Aug 15;326(1):57-66 [15262495.001]
  • [Cites] Gene Ther. 2004 Sep;11(17):1331-41 [15229628.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4448-61 [15319446.001]
  • [Cites] J Virol. 2004 Oct;78(19):10598-605 [15367627.001]
  • [Cites] FEBS Lett. 1993 May 3;322(1):21-4 [8387026.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):833-9 [8387290.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2330-7 [7683572.001]
  • [Cites] J Gen Virol. 1993 May;74 ( Pt 5):791-801 [8388016.001]
  • [Cites] J Virol. 1993 Sep;67(9):5605-16 [8394463.001]
  • [Cites] J Virol. 1993 Dec;67(12):7705-10 [7901430.001]
  • [Cites] J Biol Chem. 1994 Apr 22;269(16):11902-11 [8163489.001]
  • [Cites] Proc Natl Sci Counc Repub China B. 1993 Oct;17(4):159-63 [8171167.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5278-89 [8035806.001]
  • [Cites] J Virol. 1994 Oct;68(10):6567-77 [8083993.001]
  • [Cites] J Virol. 1995 May;69(5):2932-45 [7707519.001]
  • [Cites] J Virol. 1995 Jun;69(6):3381-8 [7745684.001]
  • [Cites] Cancer Gene Ther. 1994 Dec;1(4):267-77 [7627817.001]
  • [Cites] J Virol. 1995 Sep;69(9):5607-20 [7637007.001]
  • [Cites] Nucleic Acids Res. 1995 Jul 25;23(14):2614-20 [7651822.001]
  • [Cites] J Virol. 1995 Oct;69(10):6553-6 [7666558.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4599-605 [7553636.001]
  • [Cites] Cancer Gene Ther. 1995 Dec;2(4):263-71 [8548580.001]
  • [Cites] J Virol. 1996 Apr;70(4):2339-49 [8642661.001]
  • [Cites] J Virol. 1996 Jun;70(6):3355-62 [8648665.001]
  • [Cites] J Virol. 1996 Jul;70(7):4691-9 [8676495.001]
  • [Cites] J Virol. 1996 Oct;70(10):7233-5 [8794373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):163-8 [8990179.001]
  • [Cites] J Virol. 1997 Jul;71(7):5161-72 [9188583.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3993-9 [9307284.001]
  • [Cites] J Virol. 1997 Dec;71(12):9096-107 [9371566.001]
  • [Cites] Oncogene. 1997 Nov 6;15(19):2303-19 [9393875.001]
  • [Cites] J Virol. 1998 Feb;72(2):1504-15 [9445054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1189-94 [9448307.001]
  • [Cites] Mol Cell. 1998 Jan;1(2):255-64 [9659922.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22648-56 [9712894.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):1109-15 [12440984.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14088-93 [9826658.001]
  • [Cites] Virology. 1998 Nov 25;251(2):253-63 [9837789.001]
  • [Cites] J Virol. 1999 Jan;73(1):29-36 [9847303.001]
  • [Cites] J Virol. 1999 Apr;73(4):3062-70 [10074156.001]
  • [Cites] J Virol. 1999 Apr;73(4):3505-10 [10074210.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11832-41 [10207001.001]
  • [Cites] J Virol. 1999 Jun;73(6):4972-82 [10233959.001]
  • [Cites] J Virol. 1999 Sep;73(9):7185-92 [10438805.001]
  • [Cites] Gene Ther. 1999 Jun;6(6):1114-9 [10455414.001]
  • [Cites] J Virol. 2004 Dec;78(23):12762-72 [15542628.001]
  • [Cites] J Virol. 2004 Dec;78(23):12901-9 [15542642.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] J Virol. 2005 Mar;79(6):3309-21 [15731225.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S34-42 [15753010.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S43-51 [15753011.001]
  • [Cites] J Virol. 2005 Apr;79(7):4270-88 [15767428.001]
  • [Cites] J Virol. 2005 Apr;79(8):4918-26 [15795277.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • (PMID = 16720315.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC010357-06; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 152
  • [Other-IDs] NLM/ NIHMS8367; NLM/ PMC1472295
  •  go-up   go-down


15. Ponce-Camacho MA, Diaz de Leon-Medina R, Miranda-Maldonado I, Garza-Guajardo R, Hernandez-Salazar J, Barboza-Quintana O: A 5-year-old girl with a congenital ganglioneuroma diagnosed by fine needle aspiration biopsy: a case report. Cytojournal; 2008;5:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ganglioneuroma is a rare, benign, neuroblastic tumor arising mainly from the central or peripheral autonomic nervous system, especially the sympathetic system.
  • CASE PRESENTATION: A 5-year-old girl presented with a mass in the cervical region since birth.
  • Laboratory routine tests were within normal limits, ultrasonography demonstrated a solid and well-circumscribed lesion in the soft tissues of the cervical region.
  • A diagnosis of ganglioneuroma was suggested.
  • Core biopsy and surgical resection confirmed this diagnosis.
  • CONCLUSION: Congenital ganglioneuroma of the cervical region is an uncommon soft tissue benign neoplasm of neuroblastic origin, and it should be considered in the differential diagnosis of head and neck pediatric soft tissue tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 2006 Feb;70(2):287-94 [16102846.001]
  • [Cites] Diagn Cytopathol. 2005 Jun;32(6):363-6 [15880712.001]
  • [Cites] Nepal Med Coll J. 2006 Dec;8(4):288-91 [17357653.001]
  • [Cites] Clin Orthop Relat Res. 1989 Sep;(246):102-5 [2766597.001]
  • [Cites] Acta Cytol. 1993 Jul-Aug;37(4):552-4 [8328252.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):385-7 [9812237.001]
  • [Cites] Diagn Cytopathol. 1999 Sep;21(3):194-6 [10450105.001]
  • [Cites] Pediatr Dev Pathol. 2000 Mar-Apr;3(2):184-99 [10679039.001]
  • [Cites] Cytopathology. 2000 Apr;11(2):133-4 [10772014.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jan;124(1):115-6 [11228466.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jun;124(6):702-4 [11391270.001]
  • [Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1217-8 [11520276.001]
  • [Cites] Acta Cytol. 2002 Nov-Dec;46(6):1049-55 [12462081.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):239-42 [12775986.001]
  • [Cites] Arch Ophthalmol. 2004 Nov;122(11):1712-4 [15534137.001]
  • [Cites] Audiol Neurootol. 2007;12(3):160-4 [17259702.001]
  • (PMID = 18373875.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359765
  •  go-up   go-down


16. Yoshioka K, Kawahara N, Murakami H, Demura S, Kawaguchi M, Oda M, Matsumoto I, Tomita K: Cervicothoracic giant cell tumor expanding into the superior mediastinum: total excision by combined anterior-posterior approach. Orthopedics; 2009 Jul;32(7):531
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervicothoracic giant cell tumor expanding into the superior mediastinum: total excision by combined anterior-posterior approach.
  • This article describes a case of cervicothoracic giant cell tumor expanding into the superior mediastinum treated by total spondylectomy.
  • The spinal cord was severely compressed by the tumor mass.
  • The tumor had spread from T2 to the mediastinum, so that the tumor was in contact with many vital structures.
  • To resect the tumor completely, total spondylectomy from T1 to T3 was performed through a combined anterior-posterior approach.
  • The tumor was dissected from the vital structures using an anterior low cervical approach and splitting one-third of the sternum.
  • En bloc vertebral resection from Th1 to Th3, including the tumor pseudocapsule, was possible through a posterior approach.
  • The tumor around the nerve roots or dura was resected piece by piece since it was possible to separate the capsulated tumor from the dura.
  • Splitting one-third of the sternum allowed separation of the tumor from the anterior vital structures, under direct vision.
  • This allowed en bloc vertebral resection of the tumor that had spread to the mediastinum from T2 and in the craniocaudal direction from T1 to T3.
  • Although giant cell tumor is benign, it can be locally aggressive.
  • Complete excision of a giant cell tumor is the best treatment option even for the cervicothoracic spine, to protect the vital structures or neural function.
  • [MeSH-major] Giant Cell Tumors / diagnosis. Giant Cell Tumors / surgery. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Osteotomy / methods. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634835.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sun JJ, Wang ZY, Xie JC, Li ZD, Ma CC, Liu B, Zhao JZ: [Comparative analysis between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas]. Beijing Da Xue Xue Bao; 2010 Apr 18;42(2):183-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative analysis between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas].
  • OBJECTIVE: To comparatively analyze the different and common points between multi-segments intramedullary spinal cord congenital tumors and benign ependymomas, such as the patient's age, gender, nervous functions and tumor location, longitudinal extension, and removed extent.
  • METHODS: Data were studied from 12 patients with multi-segments intramedullary spinal cord congenital tumors and 19 patients with multi-segments intramedullary spinal cord benign ependymomas who underwent microsurgery for the tumor using a posterior approach.
  • The tumor was exposed through dorsal myelotomy.
  • Independent sample t-test was performed for ages, preoperative IJOA scores, postoperative IJOA scores and IJOA difference values of the patients, and longitudinal extension of tumors in the two groups with congenital tumors and benign ependymomas.
  • Two independent sample Mann-Whitney tests was performed for the patient's gender, stool and urine functions, limbs weakness, and tumor removed extent in the two groups.
  • RESULTS: The average age of patients in congenital tumors group was 23.5+/-14.3, and in benign ependymomas group was 37.8+/-12.9, the age difference between the two groups was statistically significant (t=-2.89, P=0.007).
  • 78.9 (15/19) percent of multi-segments intramedullary spinal cord benign ependymomas were located at the cervical and cervicothoracic segments.
  • Total or nearly total resection was achieved in 94.7% (18/19) patients with benign ependymomas.
  • CONCLUSION: It is known from the clinical files that most multi-segments intramedullary spinal cord congenital tumors are found in young patients and most benign ependymomas in the middle-aged.
  • Most benign ependymomas are located at the cervical and cervicothoracic segments, and they are easy to totally remove.
  • [MeSH-major] Ependymoma / surgery. Spinal Cord Neoplasms / congenital. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Microsurgery / methods. Neurosurgical Procedures / methods. Teratoma / congenital. Teratoma / diagnosis. Teratoma / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396361.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA: Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol; 2006 Nov;126(5):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pax-5 expression also was found readily in benign and malignant mesonephric tissues and focally in müllerian duct-derived tissues and tumors.
  • Together, these results are important for correct interpretation of results in immunophenotyping of undifferentiated tumors, for diagnosis of mesonephric carcinoma, and, potentially, for correct classification of neuroendocrine tumors in small biopsy samples.
  • [MeSH-minor] Adult. Blotting, Western. Cell Line, Tumor. Female. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050077.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
  •  go-up   go-down


19. Ferris RL, Xi L, Raja S, Hunt JL, Wang J, Gooding WE, Kelly L, Ching J, Luketich JD, Godfrey TE: Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck. Cancer Res; 2005 Mar 15;65(6):2147-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck.
  • Clinical staging of cervical lymph nodes from patients with squamous cell carcinoma of the head and neck (SCCHN) has only 50% accuracy compared with definitive pathologic assessment.
  • We used quantitative reverse transcription-PCR (QRT-PCR) to screen 40 potential markers for their ability to detect SCCHN metastases to cervical lymph nodes.
  • Seven markers were identified with good characteristics for identifying metastatic disease, and these were validated using a set of 26 primary tumors, 19 histologically positive lymph nodes, and 21 benign nodes from patients without cancer.
  • Four markers discriminated between positive and benign nodes with accuracy >97% but only one marker, pemphigus vulgaris antigen (PVA), discriminated with 100% accuracy in both the observed data and a statistical bootstrap analysis.
  • The automated analysis with PVA provided perfect discrimination between histologically positive and benign lymph nodes and correctly identified two lymph nodes with micrometastatic tumor deposits.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Lymph Nodes / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781625.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA90665-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Vaid L, Gupta M, Gupta N, Singh PP: Bleomycin sclerotherapy in a rare case of adult-onset cervical lymphangioma. Ear Nose Throat J; 2010 Jan;89(1):E23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin sclerotherapy in a rare case of adult-onset cervical lymphangioma.
  • Cervical lymphangioma in adults is a rare, benign tumor.
  • We describe the case of a 60-year-old woman who presented with two lymphangiomas in the cervical area-one in the upper cervical area just below the angle of the mandible and the other in the submental area.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Bone Neoplasms / drug therapy. Lymphangioma / drug therapy. Sclerotherapy / methods

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20155685.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


21. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in cervical pathology.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In this review, I discuss applications of immunohistochemistry in diagnostic cervical pathology with a particular focus on recent developments.
  • Although much of this review focuses on glandular lesions, the value of markers, such as MIB1 and p16, in the assessment of pre-invasive cervical squamous lesions is discussed.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • Rarely ectopic prostatic tissue occurs in the cervix, which can be confirmed by positive staining with prostatic markers.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


22. Lin G, Ho KC, Wang JJ, Ng KK, Wai YY, Chen YT, Chang CJ, Ng SH, Lai CH, Yen TC: Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging; 2008 Jul;28(1):128-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T.
  • PURPOSE: To evaluate diffusion-weighted imaging (DWI) for detection of pelvic lymph node metastasis in patients with cervical and uterine cancers.
  • RESULTS: The relative ADC values between tumor and nodes were significantly lower in metastatic than in benign nodes (0.06 vs. 0.21 x 10(-3) mm(2)/s, P < 0.001; cutoff value 0.10 x 10(-3) mm(2)/s).
  • CONCLUSION: The combination of size and relative ADC values was useful in detecting pelvic lymph node metastasis in patients with cervical and uterine cancers.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Lymphatic Metastasis. Uterine Cervical Neoplasms / diagnosis. Uterine Neoplasms / diagnosis


23. Zhou YA, Huang JH, Wan CY, Zuo ZB: [Surgical treatment and effect observation of cervical intraspinal benign neoplasms]. Zhongguo Gu Shang; 2009 Nov;22(11):856-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and effect observation of cervical intraspinal benign neoplasms].
  • OBJECTIVE: To investigate the diagnosis, surgical procedure and clinical outcome of cervical intraspinal benign neoplasm.
  • Cervical stability in 11 cases was restored after removal of tumors.
  • The average recover ratio of total was (46.7 +/- 2.46)%, cervical stability was (62.37 +/- 3.58)%, the other methods was (41.21 +/- 4.63)%.
  • CONCLUSION: The surgical exairesis for cervical intraspinal benign neoplasm has low post-operative recurrence.
  • The main reason of recurrence is not removed the tumor completely.
  • MRI is regarded the effective method which is helpful in differential diagnosis and surgery guidance.
  • [MeSH-major] Cervical Vertebrae / pathology. Cervical Vertebrae / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084949.001).
  • [ISSN] 1003-0034
  • [Journal-full-title] Zhongguo gu shang = China journal of orthopaedics and traumatology
  • [ISO-abbreviation] Zhongguo Gu Shang
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Qiao X, Bhuiya TA, Spitzer M: Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis; 2005 Apr;9(2):100-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis.
  • OBJECTIVE: In postmenopausal women, differentiating high-grade cervical intraepithelial neoplasia (CIN 2,3) from atrophic uterine cervical squamous epithelium histologically may pose a diagnostic challenge.
  • In this study, we compared the staining features of Ki-67, cyclin E, and p16 in cervix specimens from postmenopausal women to distinguish CIN 2,3 from atrophy.
  • METHODS: Twenty-six formalin-fixed paraffin-embedded archival cervical specimens (4 biopsy, 8 laser cone, and 14 total hysterectomy samples) were selected from 25 women 50 to 80 years of age (mean = 64 years).
  • In coexistent CIN 2,3 and atrophy cases, the three-antibody panel clearly demarcated the transition from benign to neoplastic epithelia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Atrophy. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Postmenopause / metabolism


25. Satsuka A, Sakai H: [Life cycle of HPV governed by the differentiation program of epithelial cell]. Uirusu; 2008 Dec;58(2):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillomavirus is a pathogenic virus that induces benign tumor at the infected lesion, and its association with malignant tumor was first identified by R.
  • A variety of cancers have been reported to be associated with the infection of human papillomavirus since the report by H. zur Hausen that describes a connection between the HPV infection and cervical cancer.
  • The HPV infection is broadly distributed as a sexually transmitted disease (STD) and recently the initial age diagnosed as the cervical cancer is getting lowered.
  • Because of its clinical importance, the study on HPV has been focused on the oncogenic properties, and the results of which had great impacts on the researches of the tumor suppressors, such as p53 and pRb, and "ubiquiitn-proteasome" pathway.
  • [MeSH-minor] Animals. Gene Expression Regulation, Viral. Gene Silencing. Genes, Tumor Suppressor. Genome, Viral. Humans. Open Reading Frames / genetics. Virus Replication / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374194.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 33
  •  go-up   go-down


26. Pennekamp W, Peters S, Schinkel C, Kuhnen C, Nicolas V, Muhr G, Frangen TM: Aneurysmal bone cyst of the cervical spine (2008:7b). Eur Radiol; 2008 Oct;18(10):2356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneurysmal bone cyst of the cervical spine (2008:7b).
  • Aneurysmal bone cysts (ABC) are rare, benign, but locally destructive bone tumors.
  • They occur in the spine in 14% of cases, but only 2% are found in the cervical spine.
  • This case report presents a 16-year-old female with an expansive aneurysmatic bone cyst with extensive bone destruction and instability in the cervical segments C1 and C2.
  • In CT and MRI, there was a soft-tissue tumor mass with multiple cysts and fluid-fluid levels within these cysts, as well as contrast enhancement of the cyst wall and the tissue among the cysts.
  • The tumor was resected en bloc, after which the patient underwent adjuvant radiation therapy.
  • [MeSH-major] Bone Cysts, Aneurysmal / diagnosis. Cervical Vertebrae / diagnostic imaging. Cervical Vertebrae / pathology. Magnetic Resonance Imaging. Spinal Diseases / diagnosis. Tomography, X-Ray Computed


27. Zätterström U, Thor A, Nordgren H: Cervical metastasis from Spitz nevus of the buccal mucosa. Melanoma Res; 2008 Feb;18(1):36-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical metastasis from Spitz nevus of the buccal mucosa.
  • Cytology from fine needle aspiration indicated spread of a melanocytic tumor and she underwent a modified supraomohyiod neck dissection.
  • It is believed that this may be an example of how a Spitz tumor, although inherently benign, can spread along lymphatics in a pseudometastatic fashion.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Mouth Mucosa / pathology. Mouth Neoplasms / pathology. Nevus, Epithelioid and Spindle Cell / pathology


28. Bhatnagar AK, Gerszten PC, Ozhasaglu C, Vogel WJ, Kalnicki S, Welch WC, Burton SA: CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors. Technol Cancer Res Treat; 2005 Oct;4(5):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CyberKnife Frameless Radiosurgery for the treatment of extracranial benign tumors.
  • Limited data exists for the use of radiosurgery for benign extracranial tumors.
  • The purpose of this study was to evaluate the feasibility, toxicity, and local control of patients with benign extracranial lesions treated with the CyberKnife Frameless Radiosurgery System.
  • From September 2001 thru January 2004, 59 benign tumors in 44 patients were treated using the CyberKnife a frameless image-guided radiosurgery system.
  • The anatomic locations of these tumors were spinal (25 cervical, four thoracic, 14 lumbar, and two sacral), neck (eight), orbital (three), brainstem (one), and foramen magnum (one).
  • The median tumor dose delivered was 16.0 Gy to the 80% isodose line (range 10-31 Gy).
  • The median tumor volume was 4.3 cc (range 0.14-98.6 cc).
  • This study suggests that CyberKnife Radiosurgery is a safe and efficacious treatment modality for benign tumors, even for those patients with recurrent previously irradiated lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Neurofibroma / surgery. Safety. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173828.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol; 2007 Jan;26(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
  • Early detection of premalignant and malignant glandular lesions of the uterine cervix and their distinction from benign mimics is crucial but sometimes difficult.
  • In this study, we investigated utility of expression of p16, CEA, Ki67, p53 and ER/PR in evaluating the benign, premalignant, and malignant glandular lesions of the uterine cervix.
  • A total of 35 cervical cone or LEEP cases were collected including 14 adenocarcinoma in situ (AIS), 7 endocervical glandular dysplasia (EGD), and 14 benign mimics (BM).
  • There was a loss of ER/PR in cervical AIS, but not in EGD.
  • Our results indicate that the Silverberg scoring system is a useful tool in differential diagnosis of cervical glandular lesions for increased diagnostic accuracy and interobserver agreement.
  • Most cervical glandular lesions can be differentiated by using a combination of histological scores with a panel of immunomarkers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


30. Park KJ, Soslow RA: Current concepts in cervical pathology. Arch Pathol Lab Med; 2009 May;133(5):729-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in cervical pathology.
  • CONTEXT: The correct diagnosis and reporting of cervical in situ and invasive carcinoma are essential for the appropriate clinical management of patients with human papillomavirus-associated disease.
  • OBJECTIVES: To review common mistakes made in the diagnosis of cervical dysplasia and invasive carcinoma, describe variants and benign mimics of high-grade squamous intraepithelial lesion and adenocarcinoma in situ, and discuss available ancillary studies that can be useful in making the distinctions as well as to review important factors related to prognosis that should be included in the pathology report.
  • CONCLUSIONS: There are many mimics and variants of cervical squamous and glandular lesions that can be resolved with ancillary studies and careful histologic examination.
  • Prognostically important features, such as tumor size, presence of vascular invasion, and margin status, should always be included in the pathology report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415947.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  •  go-up   go-down


31. Jozwik M, Szajda SD, Skrzydlewski Z, Jozwik M, Sulkowski S: The activity of cancer procoagulant in cases of uterine leiomyomas. Eur J Gynaecol Oncol; 2005;26(4):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The activity of cancer procoagulant in cases of uterine leiomyomas.
  • The present study was designed to test whether it is also synthesized by benign neoplastic cells, namely uterine leiomyomas.
  • MATERIALS AND METHODS: We determined the activity of CP in the blood serum of women with uterine leiomyomas (N = 24), normal women (N = 15), and genital cancer patients (N = 6) by the coagulative method according to Gordon and Benson.
  • Also, the CP activity in 10% tissue homogenates of uterine leiomyomas, normal uterine muscle and tissues of cervical and endometrial carcinoma was determined by the chromogenic method according to Colucci et al.
  • RESULTS: The mean CP activity in the sera of women with uterine leiomyomas was 181.1 seconds (s) +/- 19.9 s, in healthy women--293.2 s +/- 33.8 s, and in genital cancer patients--78.8 +/- 18.5 s (all differences: p < 0.001).
  • Similarly, in homogenates of uterine leiomyomas the CP activity was 19.6 +/- 3.8 nmoles pNa/ml, in normal uterine muscle it was 13.2 +/- 2.2 nmoles pNa/ml, and in cancerous tissue--28.0 +/- 6.6 nmol pNa/ml (all values being significantly different from each other).
  • There was a strong correlation (r = -0.8122; p < 0.001) between the CP activity in uterine leiomyomas and serum activity, suggesting that the source of the serum CP activity was from the leiomyoma.
  • The coagulation time of 120 to 240 s by the Gordon and Benson method supported the diagnosis of uterine leiomyoma, and a value below 120 s--the suspicion of genital cancer.
  • CONCLUSIONS: Uterine leiomyomas, representing benign genital neoplasia, synthesize CP and are the likely origin of CP activity in blood, as has been described for malignant tumors, but to a lesser degree.
  • There may be a role for CP as a tumor marker of genital neoplasia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cysteine Endopeptidases / biosynthesis. Leiomyoma / diagnosis. Neoplasm Proteins / analysis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Genital Neoplasms, Female / blood. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122189.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.26 / cancer procoagulant
  •  go-up   go-down


32. Abu J, Ireland D, Brown L: Adenosarcoma of an endometrial polyp in a 27-year-old nulligravida: a case report. J Reprod Med; 2007 Apr;52(4):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endometrial adenosarcoma is a rare tumor first described by Clement and Scully in 1974.
  • It consists of benign or atypical neoplastic glands within a sarcomatous stroma and represents approximately 8% of all uterine sarcomas.
  • On examination, tissue protruding from the external cervical os is a common finding, with a smaller number of patients having an enlarged uterus or palpable pelvic mass.
  • [MeSH-major] Adenosarcoma / surgery. Endometrial Neoplasms / surgery. Fertility / physiology. Polyps / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506376.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Horn EM, Nakaji P, Coons SW, Dickman CA: Surgical treatment for intramedullary spinal cord melanocytomas. J Neurosurg Spine; 2008 Jul;9(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spinal meningeal melanocytomas are rare lesions that are histologically benign and can behave aggressively, with local infiltration.
  • The charts were reviewed for patient demographics, surgical procedure, clinical outcome, and long-term tumor progression.
  • The patients' ages were 37, 37, and 48 years, and the location of their tumor was C1-3, T9-10, and T-12, respectively.
  • [MeSH-major] Nevus, Pigmented / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Cervical Vertebrae. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Thoracic Vertebrae. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590410.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


34. Avadhanam PK, Vuyyur S, Panigrahi MK: A rare occurrence of osteoblastoma in a child. J Pediatr Neurosci; 2010 Jul;5(2):153-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Decompression of the L5 nerve and resection of the tumor was performed.
  • Osteoblastoma is a rare tumor with an incidence of 1% of all tumors and 30-40% of cases involving the spine.
  • The most common area of involvement is the cervical spine followed by the lumbar spine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol India. 1999 Dec;47(4):330-1 [10625912.001]
  • [Cites] J Pediatr Orthop. 1994 Nov-Dec;14(6):788-92 [7814596.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):1044-52 [13364889.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):37-45 [1563167.001]
  • [Cites] Neurol Med Chir (Tokyo). 2005 Jul;45(7):379-83 [16041187.001]
  • [Cites] Surg Neurol. 1992 Jul;38(1):12-8 [1615369.001]
  • [Cites] J Bone Joint Surg Am. 1986 Mar;68(3):354-61 [3949831.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):559-74 [8649737.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] J Spinal Disord. 1992 Jun;5(2):204-11 [1606380.001]
  • [Cites] AJR Am J Roentgenol. 1976 Feb;126(2):321-5 [175701.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):999-1003 [1913494.001]
  • [Cites] J Spinal Disord. 1990 Jun;3(2):179-82 [2134427.001]
  • [Cites] Spine (Phila Pa 1976). 1990 Dec;15(12):1272-80 [2149206.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):884-8 [2453621.001]
  • [Cites] Surg Neurol. 1987 Apr;27(4):381-5 [3824145.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):76-85 [3956019.001]
  • [Cites] J Bone Joint Surg Br. 1973 Nov;55(4):841-7 [4766190.001]
  • [Cites] Clin Orthop Relat Res. 1974 Jan-Feb;(98):225-30 [4817234.001]
  • [Cites] J Neurosurg. 1969 Oct;31(4):468-73 [5349094.001]
  • [Cites] Neurosurgery. 1981 Jan;8(1):31-8 [7207770.001]
  • [Cites] J Bone Joint Surg Am. 1975 Jan;57(1):1-9 [1123354.001]
  • (PMID = 21559167.001).
  • [ISSN] 1998-3948
  • [Journal-full-title] Journal of pediatric neurosciences
  • [ISO-abbreviation] J Pediatr Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3087998
  • [Keywords] NOTNLM ; Benign tumors of spine / osteoblastoma / osteoblastoma in childhood
  •  go-up   go-down


35. Wang X, Kumar D, Seidman JD: Uterine lipoleiomyomas: a clinicopathologic study of 50 cases. Int J Gynecol Pathol; 2006 Jul;25(3):239-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine lipoleiomyomas: a clinicopathologic study of 50 cases.
  • Lipoleiomyoma is an uncommon uterine neoplasm and, although presumed to be benign, has been inadequately studied.
  • Confirming the benign nature of this tumor is important because it can closely resemble well-differentiated liposarcoma.
  • We evaluated 50 consecutive lipoleiomyomas diagnosed at the Washington Hospital Center from 1998 to 2004; 2.1% of patients who had uterine leiomyomas during this period had a lipoleiomyoma.
  • The mean and median tumor size was 4.6 and 2.1 cm, respectively.
  • Forty-three (83%) tumors were located in the uterine corpus, and 7 (13%) were in the cervix.
  • One broad ligament tumor and one retroperitoneal tumor were also studied.
  • There were no recurrences or fatalities related to tumor.
  • Lipoleiomyoma of the uterus seems to have an uneventful clinical course and can now be confidently regarded as benign.
  • [MeSH-major] Leiomyoma / pathology. Lipoma / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


36. Fukunari F, Okamura K, Zeze R, Kagawa T, Hashimoto K, Yuasa K: Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):890-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture.
  • STUDY DESIGN: The signal intensities of 98 cervical lymph nodes from 20 patients with oral squamous cell carcinoma were evaluated on T2-weighted and diffusion-weighted whole-body imaging with background body signal suppression (DWIBS).
  • Using DWIBS images with inverted black-and-white image contrast, cystic degeneration, keratinization, fibrous tissue, tumor tissue, and lymphoid tissue were either hypointense or intermediate in intensity.
  • Using DWIBS images, it was difficult to differentiate metastatic from benign lymph nodes.
  • [MeSH-major] Lymph Nodes / radiography. Lymphatic Metastasis / radiography. Magnetic Resonance Imaging. Mouth Neoplasms / pathology. Neoplasms, Squamous Cell / radiography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20299250.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Gardikis S, Kambouri K, Tsalkidis A, Chatzimicael A, Vaos G: Lipoblastoma on the posterior side of the neck. Turk J Pediatr; 2009 May-Jun;51(3):287-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoblastoma is a rare benign pediatric tumor derived from embryonic fat, and only two cases of lipoblastoma located on the posterior side of the neck have been reported in the literature.
  • Here, we present the third case of posterior neck lipoblastoma in a 13-month-old healthy girl, who presented with a firm, posterior cervical mass.
  • The tumor was completely resected following ultrasonography, computerized tomography, and magnetic resonance imaging evaluations.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Lipoma / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817275.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


38. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
  • Endometrial carcinomas, particularly of endometrioid type, can invade the myometrium or cervix without eliciting a stromal desmoplastic or inflammatory response and have been referred to as diffusely infiltrating endometrial carcinomas.
  • The neoplasms consisted of 12 endometrioid carcinomas, 1 mixed endometrioid and clear cell carcinoma, and 1 serous carcinoma.
  • Seven cases exhibited cervical stromal involvement and in 2 there was involvement of both ovaries in a similar pattern.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


39. Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res; 2005 Nov 15;11(22):8063-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
  • The aim of this study is to investigate the expression pattern of VEGF-C immunoreactive protein in PTC and its relationship with cervical lymph node metastasis.
  • EXPERIMENTAL DESIGN: Tissue samples were obtained from 39 specimens of PTC (20 with and 19 without lymph node metastasis) as well as 20 benign thyroid nodules.
  • Overexpression of the VEGF-C protein was evaluated by immunoblotting with specific anti-VEGF-C antibody in paired tumor and nontumor tissues from PTC.
  • RESULTS: Overexpression of VEGF-C was detected in 69% of the PTC and in 5% of the benign thyroid specimens.
  • When comparing between the metastatic and nonmetastatic groups of PTC, a higher expression level of VEGF-C was detected in both the tumor (P = 0.004) and adjacent nontumor tissues (P = 0.011).
  • Positive immunostaining for VEGF-C was confirmed in PTC tumor tissues and metastatic lymph nodes, which correlated with flt-4-positive vessel density in tumor and peritumor tissues.
  • VEGF-C expression may play a role in lymphangiogenesis of PTC and further study is necessary to evaluate the clinical application of VEGF-C as a molecular marker for tumor metastases to cervical lymph nodes.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology. Vascular Endothelial Growth Factor C / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16299237.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


40. Poliani PL, Sperli D, Valentini S, Armentano A, Bercich L, Bonetti MF, Corriero G, Brisigotti M, Quattrone A, Lanza PL: Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case. Neuropathology; 2009 Oct;29(5):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioneuronal tumor with neuropil-like islands and meningeal dissemination: histopathological and radiological study of a pediatric case.
  • Cerebral and spinal location of glioneuronal tumors have been recently described as a novel type of primary CNS neoplasia.
  • In the present report we describe a case of a 15-month-old child with a spinal GTNI of the cervical region and meningeal dissemination.
  • Histologically the tumor was composed of round, small neurocytic-like cells arranged around eosinophilic neuropil cores and embedded in a diffuse fibrillar glial component forming prominent "rosetted" neuropil islands displaying strong immunoreactivity for neuronal markers.
  • Nevertheless, due to their exceptional rarity, the natural history of these lesions is not yet fully understood, but spinal GTNI seems to have an unfavorable clinical course despite their benign histopathological features, which must be taken into account for appropriate treatment and follow-up of the patient.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Nerve Tissue / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Cervical Vertebrae. Fatal Outcome. Humans. Infant. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077041.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


41. Daniel E, McGuirt WF Sr: Neck masses secondary to heterotopic salivary gland tissue: a 25-year experience. Am J Otolaryngol; 2005 Mar-Apr;26(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of this study is to review salivary tumors arising from heterotopic salivary inclusions in the periparotid and cervical lymph nodal tissues over a 25-year span.
  • METHODS: A retrospective chart review revealed 24 patients with asymptomatic neck masses treated between 1976 and 2001, whose pathology demonstrated heterotopic salivary tissue or neoplasms arising from heterotopic salivary tissue.
  • RESULTS: Nine cases were benign periparotid lymph nodes with heterotopic salivary inclusions, 3 of which had multimodal involvement.
  • The benign tumors were predominantly Warthin's tumor (8) with 1 pleomorphic adenoma.
  • Among the 15 tumor patients, follow-up ranged from 1 month to 17 years.
  • CONCLUSIONS: Heterotopic salivary tissue in periparotid and upper cervical nodes is a more common occurrence than historically recognized.
  • Tumorigenic changes arise from heterotopic nodal inclusions, and although infrequent, should be considered in the differential diagnosis for isolated neck/periparotid masses and parotid Warthin's tumor.
  • Isolated low-grade malignant lesions/benign lesions are adequately managed by excision or parotidectomy alone.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Choristoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742261.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. de León DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, Cetina L, Coronel A, Hes O: Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer; 2009;9:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonetheless, in 50-80% of cases known risk factors have not been identified, this has generated the attempt to identify new factors related with this neoplasia as viral infections.
  • The aim of this work is investigate the prevalence of HPV DNA in patients with breast lesions at the Instituto Nacional de Cancerologia de Mexico.
  • METHODS: Fifty-one cases of breast cancer were selected from the files of the institute and compared by age and tumor size with 43 cases of non malignant breast lesions (fibroadenoma, fibrocystic disease and phyllodes tumor).
  • RESULTS: All patients were mexican, mean age was 53.3, median age of menarche was 13 and median tumor size 9 cms.
  • Cervicovaginal cytology was performed to all patients, 1 patient (1.9%) of cancer group had HPV and none in the other group, no cases were diagnosed with cervical dysplasia.
  • In the group of benign conditions all were negative to HPV-DNA.
  • [MeSH-major] Breast Neoplasms / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):172-7 [17088061.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]
  • [Cites] Acta Oncol. 1999;38(7):931-8 [10606422.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5057-61 [10697510.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):946-8 [16222323.001]
  • [Cites] Clin Breast Cancer. 2005 Dec;6(5):391-401 [16381622.001]
  • [Cites] J Pathol. 2006 Aug;209(4):436-44 [16710841.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):55-8 [17624590.001]
  • (PMID = 19161629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2636825
  •  go-up   go-down


43. Xu F, Liu B, Chen XY, Zhou EX, Fan DF, Ma Y, Tang ZH: [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Feb;11(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
  • OBJECTIVE: To explore the clinical characteristics, diagnosis and therapy of thyroid carcinoma in children.
  • RESULTS: A hard thyroid mass was observed in 10 out of 12 children with thyroid carcinoma, but only one out of 15 children with benign thyroid tumor (<0.05).
  • The rate of cervical lymph node metastasis in children with thyroid carcinoma was significantly higher than that in children with benign thyroid tumor (<0.05).
  • Nine patients (75%) had cervical lymph node metastasis.
  • Unilateral lobectomy plus isthmectomy along with a functional cervical lymph node dissection was a primary operation mode (83%).
  • CONCLUSIONS: Childhood thyroid carcinoma is mostly differentiated and characterized by hard thyroid mass and cervical lymph node metastasis.
  • A combination of ultrasonography and CT is helpful to the diagnosis of childhood thyroid carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222949.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


44. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


45. McCall T, Rao G, Jensen R: Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma. J Neurooncol; 2006 Nov;80(2):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and rapid growth of a desmoid tumor in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • Desmoid tumors are histologically benign but locally invasive tumors that can occur in the head and neck.
  • We present the rare case of a desmoid tumor that occurred in the surgical corridor after suboccipital craniotomy for recurrent low-grade astrocytoma.
  • The mass was resected en bloc.
  • Histology demonstrated clear surgical margins and a tumor of low cellularity consistent with a desmoid tumor.
  • Desmoid tumors should be considered in the differential diagnosis for superficial masses occurring in the surgical bed after posterior cervical surgery.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / pathology. Fibromatosis, Aggressive / pathology. Postoperative Complications / pathology

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1973 Jul;39(1):114-6 [4717135.001]
  • [Cites] Cancer. 1960 Jul-Aug;13:825-36 [14405434.001]
  • [Cites] Clin Orthop Relat Res. 2000 Jun;(375):207-13 [10853171.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2045-52 [10570430.001]
  • [Cites] Orthop Rev. 1987 Jul;16(7):481-8 [3331192.001]
  • [Cites] Acta Chir Scand. 1979;145(8):563-9 [539343.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):70-9 [11146782.001]
  • [Cites] Am J Surg. 1966 Oct;112(4):615-22 [5915310.001]
  • [Cites] Tumori. 2005 Jul-Aug;91(4):325-30 [16277098.001]
  • [Cites] Neurosurgery. 1999 Oct;45(4):875-81; discussion 881-2 [10515483.001]
  • [Cites] Br J Surg. 1995 Apr;82(4):510-4 [7613897.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):191-6 [2916941.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2051-5 [6488135.001]
  • [Cites] Radiology. 1977 Jul;124(1):225-6 [405711.001]
  • [Cites] Cancer. 1967 Jul;20(7):1131-40 [6027003.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):674-80 [7091047.001]
  • [Cites] J Bone Joint Surg Am. 1996 Jun;78(6):848-54 [8666602.001]
  • [Cites] Surgery. 1969 Feb;65(2):241-6 [4237097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):325-8 [8892455.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):866-72; discussion 872-3 [10363901.001]
  • [Cites] Br J Surg. 2000 May;87(5):608-13 [10792318.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):152-6 [15170654.001]
  • [Cites] Surgery. 1964 Sep;56:497-504 [14215706.001]
  • [Cites] Am J Surg. 1988 Oct;156(4):327-31 [3177760.001]
  • [Cites] Head Neck. 2000 Dec;22(8):814-21 [11084643.001]
  • [Cites] Am J Hum Genet. 1962 Dec;14:376-90 [13946545.001]
  • [Cites] J Bone Joint Surg Am. 1984 Dec;66(9):1369-74 [6501332.001]
  • [Cites] J Thorac Cardiovasc Surg. 1963 Aug;46:242-51 [14049009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1167-71 [6409853.001]
  • [Cites] World J Surg Oncol. 2005 Jul 21;3:49 [16042767.001]
  • [Cites] Arch Pathol. 1961 Feb;71:214-21 [13706852.001]
  • (PMID = 16645711.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Muzumdar D, Ventureyra EC: Tonsillar herniation and cervical syringomyelia in association with posterior fossa tumors in children: a case-based update. Childs Nerv Syst; 2006 May;22(5):454-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar herniation and cervical syringomyelia in association with posterior fossa tumors in children: a case-based update.
  • The symptomatology is predominantly directed towards the tumor.
  • CASE REPORT: We describe a case of a pilocytic astrocytoma of the cerebellum in a 13-year-old girl who presented with clinical features of progressively worsening raised intracranial pressure and secondary tonsillar herniation and cervical syringomyelia.
  • Magnetic resonance (MR) imaging showed a large midline inhomogenously enhancing vermian tumor causing moderate obstructive hydrocephalus.
  • The tumor was resected through a suboccipital craniectomy.
  • At follow-up after 3 months, MR imaging demonstrated total resolution of tonsillar herniation and cervical syringomyelia.
  • CONCLUSIONS: The occurrence of tonsillar herniation and syringomyelia in association with a slow growing benign tumor like pilocytic astrocytoma of the cerebellum is uncommon.
  • Surgical extirpation of the tumor restores the normal cerebrospinal fluid circulation at the foramen magnum and produces an excellent outcome.
  • [MeSH-major] Astrocytoma. Hernia / etiology. Infratentorial Neoplasms / complications. Palatine Tonsil / pathology. Syringomyelia / etiology

  • Genetic Alliance. consumer health - Syringomyelia.
  • MedlinePlus Health Information. consumer health - Hernia.
  • MedlinePlus Health Information. consumer health - Syringomyelia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):11-7 [3101451.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Aug;37(8):624-6 [9301200.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):214-23; discussion 223-4 [7969828.001]
  • [Cites] Br J Neurosurg. 1996 Aug;10(4):409-11 [8864510.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(3):293-301; discussion 301-2 [10819260.001]
  • [Cites] Br J Neurosurg. 1989;3(6):669-74 [2627286.001]
  • [Cites] Clin Neuropathol. 1998 Nov-Dec;17(6):305-10 [9832257.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Dec;33(12):833-5 [7512230.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):E279-83 [12865864.001]
  • [Cites] Neurol India. 2000 Mar;48(1):81-3 [10751821.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 Sep;9(5):867-73 [3140628.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):512-5 [8235977.001]
  • [Cites] Neurochirurgie. 1979 Apr 19-21;25 Suppl 1:9-22 [481676.001]
  • [Cites] J Neurol Sci. 2004 May 15;220(1-2):3-21 [15140600.001]
  • [Cites] Clin Neurosurg. 1958;6:131-40 [13826542.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):962-8 [9609289.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1065-75; discussion 1075-6 [10232540.001]
  • [Cites] Radiology. 1991 Feb;178(2):467-74 [1987610.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):291-4 [3975813.001]
  • [Cites] Surg Neurol. 1987 Feb;27(2):187-90 [3810449.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1977 Jan;40(1):80-8 [845611.001]
  • [Cites] J Neurol. 1980;222(4):219-25 [6154780.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1102-10 [9361064.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):741-2 [12181709.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):273-84 [7241155.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(1-2):38-43 [8748866.001]
  • [Cites] Neurosurgery. 1991 May;28(5):639-45 [1876240.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):571-9 [3088935.001]
  • [Cites] Neuroradiology. 1990;32(5):371-91 [2259432.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):385-8 [12021887.001]
  • [Cites] J Neurosurg. 1995 May;82(5):802-12 [7714606.001]
  • [Cites] Neurol Res. 1986 Sep;8(3):130-45 [2877406.001]
  • [Cites] J Neurosurg. 1990 Jan;72(1):133-8 [2294173.001]
  • [Cites] Neurol India. 2001 Sep;49(3):323 [11593259.001]
  • [Cites] Br J Neurosurg. 1998 Feb;12(1):33-6 [11013645.001]
  • [Cites] Br J Neurosurg. 2004 Feb;18(1):70-1 [15040721.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 May;30(5):324-8 [1699148.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):3-15 [8271018.001]
  • [Cites] Lancet. 1970 Jun 6;1(7658):1234 [4192419.001]
  • [Cites] Neuroradiology. 1996 Aug;38(6):529-31 [8880711.001]
  • [Cites] Lancet. 1972 Oct 14;2(7781):799-801 [4116236.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1069-74 [8584146.001]
  • [Cites] Surg Neurol. 1995 May;43(5):470-5; discussion 475-7 [7660286.001]
  • [Cites] Eur Neurol. 1974;12(2):116-27 [4139014.001]
  • [Cites] Acta Pathol Jpn. 1992 Jan;42(1):25-34 [1557985.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 Jan-Feb;4(1):73-8 [6402905.001]
  • [Cites] J Neurol. 1982;227(2):67-73 [6180141.001]
  • [Cites] J Neurosurg. 1997 May;86(5):907 [9126912.001]
  • (PMID = 16397818.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Ling J, Wiederkehr U, Cabiness S, Shroyer KR, Robinson JP: Application of flow cytometry for biomarker-based cervical cancer cells detection. Diagn Cytopathol; 2008 Feb;36(2):76-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of flow cytometry for biomarker-based cervical cancer cells detection.
  • The Pap test used for cervical cancer screening is subjective, labor-intensive, and has relatively low sensitivity and specificity for the detection of underlying clinically significant lesions.
  • The objective of this study is to develop a biomarker/flow cytometry-based approach for cervical cancer screening.
  • Immunofluorescence technology to quantify cervical cell expression of two biomarkers p16(INK4A) and Mcm5 was developed and evaluated by both microscopy and flow cytometry.
  • The capability of using biomarker/flow cytometry approach to detect rare-event dysplastic cells in a large background of benign epithelial and inflammatory cells was evaluated.
  • The results indicate that flow cytometry could detect 0.01% dysplastic cells in a background of normal cervical epithelial cells with the combination of the two biomarkers.
  • Thirty-two clinical specimens were used to test the biomarker/flow cytometry-based approach and the results were compared with the liquid-based cervical cytology.
  • The experiment yielded 100% sensitivity and 93% specificity with reference to the liquid-based cervical cytology.
  • This study indicates the promise of using multi-color fluorescence flow cytometry for biomarker-based cervical cancer screening.
  • This molecular-based, potentially high-throughput and automated method is expected to provide an alternative/auxiliary means of cervical cancer screening.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Flow Cytometry / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biopsy. Cervix Uteri / metabolism. Cervix Uteri / pathology. Female. HeLa Cells. Humans. Mass Screening / methods. Sensitivity and Specificity


48. Choudry Q, Younis F, Smith RB: Intraosseous schwannoma of D12 thoracic vertebra: diagnosis and surgical management with 5-year follow-up. Eur Spine J; 2007 Dec;16 Suppl 3:283-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraosseous schwannoma of D12 thoracic vertebra: diagnosis and surgical management with 5-year follow-up.
  • Intraosseous schwannomas or neurilemomas are rare benign neoplasms that account for less than 0.2% of primary bone tumours.
  • MRI showed a tumor occupying the D12 vertebrae with perivertibral protrusion compressing the thecal sac.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery. Thoracic Vertebrae / pathology. Thoracic Vertebrae / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1967 Jun;47(6):759-66 [6025077.001]
  • [Cites] J Bone Joint Surg Am. 1971 Mar;53(2):349-55 [5546707.001]
  • [Cites] Radiology. 1972 Feb;102(2):325-6 [5009933.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):271-82 [1277675.001]
  • [Cites] J Bone Joint Surg Am. 1956 Apr;38-A(2):377-91 [13319400.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2650-7 [1423195.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1219-22 [9802868.001]
  • [Cites] Radiology. 1960 Aug;75:215-22 [14441281.001]
  • [Cites] Hum Pathol. 1984 Jun;15(6):551-8 [6724574.001]
  • (PMID = 17082954.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2148077
  •  go-up   go-down


49. Tosun G, Sendag F, Zeybek B, Cosan Terek M, Guven C, Zekiogly O, Bilgin O: Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue. Eur J Gynaecol Oncol; 2010;31(6):627-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue.
  • PURPOSE OF INVESTIGATION: To evaluate the immunohistochemical expressions of p16 and p53 in cervical intraepithelial neoplasia (CIN) and do a comparison with non-neoplastic cervical lesions.
  • CONCLUSION: While p16 is useful in detecting high-grade cervical lesions, p53 is not a good biomarker for distinguishing high-grade lesions from low grade ones.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Papillomavirus Infections / metabolism. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / metabolism

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319504.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


50. Yang YC, Lee ZY, Wu CC, Chen TC, Chang CL, Chen CP: CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int J Gynecol Cancer; 2007 May-Jun;17(3):676-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma.
  • The aim of this study is to investigate the expression of CXCR4 receptor in cervical adenocarcinoma and related mechanisms involved in pelvic lymph node metastasis.
  • Immunohistochemistry was used to evaluate the expression of CXCR4 and the association of pelvic lymph node metastasis in archived tissue from clinical stage IB cervical adenocarcinomas (n = 37) and from benign specimens obtained at hysterectomy for other causes (n = 48).
  • The HeLa cell (cervical adenocarcinoma-derived cell) line that expresses CXCR4 was used to study the interaction between the CXCR4 receptor and stromal cell-derived factor 1alpha (SDF-1alpha).
  • Only 25% of the benign specimens had weak or negative staining for CXCR4.
  • We conclude CXCR4 expression is associated with cervical adenocarcinoma cell migration and proliferation, and primary cervical adenocarcinoma cells expressing CXCR4 are significantly more likely to metastasize to pelvic lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis. Receptors, CXCR4 / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cell Survival / drug effects. Chemokine CXCL12. Chemokines, CXC / metabolism. Chemokines, CXC / pharmacology. Female. HeLa Cells. Humans. Lymph Nodes / metabolism. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Oncogene Protein v-akt / metabolism. Pelvis. U937 Cells

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504381.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


51. Zenmyo M, Ishido Y, Terahara M, Yamamoto T, Tanimoto A, Komiya S, Ijiri K: Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study. Int J Neurosci; 2010 Oct;120(10):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study.
  • Spinal subependymomas, which have a relatively benign nature, are very rare tumors.
  • A case of cervical intramedullary subependymoma in a 63-year-old female is reported.
  • Enhancement in the small part of the tumor was observed on a T1-weighted MRI with gadolinium administration.
  • The tumor occupied the left side of the spinal cord, and was totally removed through a laminoplasty of C2.
  • Immunohistochemistry was useful for pathological diagnosis.
  • [MeSH-major] Ependyma / pathology. Glioma, Subependymal / pathology. Spinal Cord / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Subependymoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942580.001).
  • [ISSN] 1563-5279
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Zou JF, Li JY, Wu XW, Chen SY: [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1252-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].
  • AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia.
  • The cervical venous blood samples were obtained at the following time points: before induction of anesthesia(T0), 30 min after anesthesia (T1), 1 h during operation (T2), 24 h after operation (T3), 48 h after operation (T4) and 72 h after operation (T5).RRCR, RRICR and RTRR were measured at different time points.
  • CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • [MeSH-major] Analgesia / adverse effects. Anesthesia / adverse effects. Erythrocytes / immunology. Laparoscopy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138693.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


53. Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S: Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res; 2005 May 1;11(9):3320-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
  • PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.
  • Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA.
  • Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied.
  • In contrast, no hK6 secretion was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and plasma concentrations (mean +/- SE) among normal healthy females (2.7 +/- 0.2 microg/L), patients with benign diseases (2.4 +/- 0.2 microg/L), and patients with endometrioid carcinoma (2.6 +/- 0.2 microg/L) were not significantly different.
  • In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005).
  • [MeSH-major] Biomarkers, Tumor / blood. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Kallikreins / blood. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867230.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


54. Li S, Meng L, Zhu C, Wu L, Bai X, Wei J, Lu Y, Zhou J, Ma D: The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. Oncol Rep; 2010 Apr;23(4):1063-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The difference of mRNA expression in blood vessels derived from DLBCL and RLNH tissues was detected, and hiwi was overexpressed in tumor vessels of lymphoma.
  • Compared with that of chronic cervicitis (CC), hyperplasia of mammary glands (HMG), ovarian benign lesions (OBL) and endometrium benign lesions (EBL), the expression of hiwi, Ang-2 and Tie-2 was increased significantly in uterine cervical cancer (UCC), breast carcinoma (BC), ovarian cancer (OC) and endometrial cancer (EC) (P<0.01).
  • [MeSH-major] Neoplasms / blood supply. Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Proteins / metabolism
  • [MeSH-minor] Angiopoietin-2 / biosynthesis. Angiopoietin-2 / genetics. Argonaute Proteins. Biomarkers, Tumor / analysis. Cell Line, Tumor. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Receptor, TIE-2 / biosynthesis. Receptor, TIE-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204292.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Argonaute Proteins; 0 / Biomarkers, Tumor; 0 / PIWIL1 protein, human; 0 / Proteins; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


55. Zhang F, Ni B, Zhao L, Chen H, Li S, Zhou F, Yang J, Tsai N: Desmoplastic fibroma of the cervical spine: case report and review of the literature. Spine (Phila Pa 1976); 2010 Jun 15;35(14):E667-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic fibroma of the cervical spine: case report and review of the literature.
  • OBJECTIVE: To present a rare case of desmoplastic fibroma (DF) in the cervical spine and discuss the diagnosis and treatment of this disorder.
  • SUMMARY OF BACKGROUND DATA: DF is an extremely rare primary tumor of bone, especially in cervical spine.
  • It is a benign but locally aggressive tumor of the connective tissue.
  • METHODS: We report on a 70-year-old woman with a DF of the fourth and fifth cervical vertebrae.
  • After radiologic evaluation, a mass lesion was found on the fourth and fifth cervical vertebral bodies.
  • A 2-level corpectomy with wide marginal resection of the tumor was performed through the anterior approach, and the histopathologic examination yielded the diagnosis of DF.
  • CONCLUSION: Patients with DF of the cervical spine may present with the arm and neck pain mimicking cervical disc disease.
  • High index of suspicion by the clinicians must be practiced to make the appropriate diagnosis, and histologic confirmation of the diagnosis is essential.
  • [MeSH-major] Cervical Vertebrae. Fibroma, Desmoplastic / surgery. Spinal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505566.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


56. Cimpean AM, Saptefrati L, Ceausu R, Raica M: Characterization of endoglin and Ki-67 expression in endothelial cells from benign and malignant lesions of the uterine cervix. Pathol Int; 2009 Oct;59(10):695-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of endoglin and Ki-67 expression in endothelial cells from benign and malignant lesions of the uterine cervix.
  • CD105 is a more specific marker of activated endothelial cells from tumor vessels and Ki-67 is used to assess the proliferation status of both tumor and endothelial cells.
  • The aim of the present study was to evaluate the status of endothelial cells using CD105 and Ki-67 immunohistochemistry in benign and malignant lesions of the uterine cervix.
  • Double stain for CD105/Ki-67 in benign and malignant lesions of the uterine cervix showed that these two markers had divergent expression on endothelial cells from associated tumor blood vessels dependent on lesion type and proliferation status of tumor cells.
  • Absence of CD105/Ki-67 coexpression in endothelial cells was correlated with histopathology of the uterine cervix lesions and tumor proliferative status.
  • The present findings suggest that CD105 expression is an early event, specific for premalignant lesions of the uterine cervix, while endothelial proliferation assessed on Ki-67 combined with the lack of CD105 expression is often associated with invasive cervical carcinoma.
  • [MeSH-major] Antigens, CD / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Endothelial Cells / metabolism. Ki-67 Antigen / metabolism. Precancerous Conditions / metabolism. Receptors, Cell Surface / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Metaplasia. Neovascularization, Pathologic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788614.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface
  •  go-up   go-down


57. Onuma K, Saad RS, Kanbour-Shakir A, Kanbour AI, Dabbs DJ: Clinical implications of the diagnosis "atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women. Cancer; 2006 Oct 25;108(5):282-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of the diagnosis "atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women.
  • The following cytomorphologic parameters were evaluated for each woman and were compared between the squamous intraepithelial lesion (SIL) follow-up group and the benign follow-up group: inflammatory background, the number of atypical cells, cell arrangement pattern, nuclear irregularity/grooves, hyperchromasia, and cell shape.
  • The cytomorphologic features were similar in the SIL follow-up group and the benign follow-up group.
  • Because of low positive predictive value for HSIL and the difficult colposcopic examination, a more conservative follow-up may be reasonable for pregnant women who have a diagnosis of ASC-H.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Neoplasms, Squamous Cell / pathology. Papillomavirus Infections / pathology. Pregnancy Complications / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Papanicolaou Test. Predictive Value of Tests. Pregnancy. Risk Factors. Tumor Virus Infections / complications. Tumor Virus Infections / epidemiology. Vaginal Smears


58. Yilmaz AD, Unlu RE, Orbay H, Sensoz O: Recurrent granular cell tumor: how to treat. J Craniofac Surg; 2007 Sep;18(5):1187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent granular cell tumor: how to treat.
  • Granular cell tumor is an uncommon lesion usually located in the head and neck region (50%) with a female sex predominance.
  • Granular cell tumor has a peculiar clinical behavior ranging from clearly benign, locally aggressive, or manifestly malignant.
  • In this article, we present a case of recurrent benign granular cell tumor with the discussion of the treatment modalities.
  • The mass was excised two times at different centers and diagnosed as granular cell tumor after the pathologic examination.
  • Cervical lymph nodes were evaluated with ultrasonography preoperatively to exclude metastasis and no pathologic lymph nodes were noted.
  • [MeSH-major] Granular Cell Tumor / pathology. Head and Neck Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912112.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Balci S, Saglam A, Usubutun A: Primary signet-ring cell carcinoma of the cervix: case report and review of the literature. Int J Gynecol Pathol; 2010 Mar;29(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell carcinoma of the cervix: case report and review of the literature.
  • Mucinous adenocarcinoma of the cervix has 5 subtypes: endocervical, intestinal, signet-ring cell, minimal deviation, and villoglandular.
  • There are only rare reports of primary signet-ring cell carcinoma of the cervix in the literature.
  • Herein we report a 53-year-old woman with cervical adenocarcinoma with signet-ring cell morphology.
  • DNA extraction from paraffin-embedded tissue revealed the presence of human papilloma virus (HPV) type 18, which supports the cervical origin of the tumor.
  • Signet-ring cell morphology can be observed in both benign and malignant lesions of the uterine cervix.
  • Histological features and immunohistochemical profiles are discussed, and a review of signet-ring cell morphology in the uterine cervix is included.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology


60. Simonson SJ, Difilippantonio MJ, Lambert PF: Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res; 2005 Sep 15;65(18):8266-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papillomaviruses, such as HPV16, cause cervical cancers, other anogenital cancers, and a subset of head and neck cancers.
  • E6 and E7, two viral oncogenes expressed in these cancers, encode multifunctional proteins best known for their ability to bind and inactivate the tumor suppressors p53 and pRb, respectively.
  • In skin carcinogenesis experiments using E6 transgenic (K14E6(WT)) mice, HPV16 E6 was found to contribute to two distinct stages in skin carcinogenesis: promotion, a step involved in the formation of benign papillomas, and progression, the step involved in the malignant conversion of benign tumors to frank cancer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166303.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CA / CA07175; United States / NCI NIH HHS / CA / CA098428; United States / NCI NIH HHS / CA / CA22443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E6 protein, Human papillomavirus type 16; 0 / Membrane Proteins; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 9007-49-2 / DNA; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


61. Langner E, Del Negro A, Akashi HK, Araújo PP, Tincani AJ, Martins AS: Schwannomas in the head and neck: retrospective analysis of 21 patients and review of the literature. Sao Paulo Med J; 2007 Jul 5;125(4):220-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT AND OBJECTIVE: Schwannomas are benign neoplasms of the peripheral nerves originating in the Schwann cells.
  • DESIGN AND SETTING: Retrospective study at Head and Neck Service, Universidade Estadual de Campinas.
  • The sites of cervical schwannomas and the intraoperative, histopathological and postoperative clinical status of these cases were studied.
  • The nerves affected included the brachial and cervical plexuses, vagus nerve, sympathetic chain and lingual or recurrent laryngeal nerve.
  • Tumor enucleation was performed in 16 patients; the other five required more extensive surgery.
  • They are generally benign, and rarely recur.
  • The recommended surgical treatment is tumor enucleation.
  • [MeSH-major] Head and Neck Neoplasms. Neurilemmoma

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992392.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 16
  •  go-up   go-down


62. Sargent RL, Hood IC: Asphyxiation caused by giant fibrovascular polyp of the esophagus. Arch Pathol Lab Med; 2006 May;130(5):725-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Giant fibrovascular polyps of the esophagus are rare, benign, "tumorlike" lesions that typically present as large pedunculated growths arising in the cervical esophagus.
  • Diagnosis is best made by upper endoscopic evaluation; surgical excision is the definitive treatment.
  • [MeSH-major] Airway Obstruction / etiology. Asphyxia / etiology. Esophageal Neoplasms / complications. Polyps / complications
  • [MeSH-minor] Biomarkers, Tumor / analysis. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683893.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


63. Khademi B, Daneshbod Y, Negahban S, Daneshbod K, Kaviani M, Mohammadianpanah M, Ashraf MJ: Biphasic parapharyngeal synovial sarcoma: a cytologic and immunocytologic report of a case. Cytojournal; 2006;3:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial magnetic resonance imaging (MRI) revealed a large tumor in the right-sided parapharyngeal space.
  • Fine needle aspiration through cervical region was performed and was reported as benign spindle cell tumor.
  • She underwent near total resection of the tumor.
  • Pathologic report disclosed the diagnosis of synovial sarcoma.
  • CONCLUSION: Due to rarity of this tumor in this region and nonspecific cytologic features, we could not differentiate this tumor from the other more common spindle cell neoplasms.
  • Considering synovial sarcoma in this region and immunocytochemistry can be helpful in rendering a correct initial diagnosis of this tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 2005 Apr;132(4):587-91 [15806051.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2003 Oct;23(5):391-5 [15108491.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Diagn Cytopathol. 2002 Aug;27(2):96-102 [12203876.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):118-23 [10888758.001]
  • [Cites] Am J Clin Pathol. 1996 Dec;106(6):769-75 [8980353.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):124-30 [7558809.001]
  • [Cites] Cytopathology. 1996 Jun;7(3):187-200 [8782991.001]
  • [Cites] J Surg Oncol. 1993 Oct;54(2):82-6 [8412164.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):673-82 [9630174.001]
  • [Cites] Arch Orthop Trauma Surg. 1980;96(1):61-7 [7377928.001]
  • (PMID = 16907985.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1562442
  •  go-up   go-down


64. Jones EE, Wells SI: Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways. Curr Mol Med; 2006 Nov;6(7):795-808
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer and human papillomaviruses: inactivation of retinoblastoma and other tumor suppressor pathways.
  • Infection with human papillomaviruses (HPVs) is a major public health burden worldwide and is associated with benign and malignant lesions of the skin and genital tract.
  • HPV causes cervical cancer, which represents the second most prevalent cancer in women worldwide.
  • [MeSH-major] Cell Transformation, Neoplastic. Cell Transformation, Viral. Papillomaviridae / physiology. Papillomavirus Infections / metabolism. Retinoblastoma Protein / physiology. Signal Transduction. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Animals. Female. Genes, Tumor Suppressor / physiology. Humans

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100604.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Number-of-references] 234
  •  go-up   go-down


65. Conscience I, Jovenin N, Coissard C, Lorenzato M, Durlach A, Grange F, Birembaut P, Clavel C, Bernard P: P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas. Eur J Dermatol; 2006 Sep-Oct;16(5):518-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recently, an increased expression of P16, a cell cycle regulatory tumor suppressor protein, has been demonstrated in cervical squamous neoplasms as a marker of malignancy.
  • OBJECTIVES: Our first aim was to evaluate P16 expression in different types of non-melanoma skin cancers compared with normal skin and benign tumors.
  • Ki67 expression in over 5% of tumour cells was observed in 69% of cutaneous carcinomas (SCC: 54%; BD: 76%; BCC: 80%) versus 16% in the group including SK (30%) and NHS (0%) (p = 0.04).
  • Overexpression of P16 was associated with a high rate of Ki67 positive tumour cells in 23/57 malignant skin tumors (40%).
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Skin Neoplasms / metabolism. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101472.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


66. Al-Waili NS, Butler GJ, Beale J, Hamilton RW, Lee BY, Lucas P: Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med Sci Monit; 2005 Sep;11(9):RA279-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy.
  • In the 1950s, HBO2 was first used as a treatment, in addition to radiation, for head and neck cancers and cervical cancer.
  • Evidences showed that HBO2 improved tumor oxygenation, and treatment with HBO2 during irradiation has been shown to improve the radiation response of many solid tumors.
  • A significant improvement in tumor response was obtained when photodynamic therapy (PDT) was delivered during hyperoxygenation.
  • HBO2 is a relatively benign with few contraindications, even for active cancer patients.
  • [MeSH-major] Hyperbaric Oxygenation. Neoplasms / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127374.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 103
  •  go-up   go-down


67. Bouilloud F, Jégoux F, Caze A, Godey B, Le Clech G: [Parapharyngeal tumors: diagnosis and treatment]. Ann Otolaryngol Chir Cervicofac; 2008 Sep;125(4):181-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parapharyngeal tumors: diagnosis and treatment].
  • [Transliterated title] Tumeurs parapharyngées: diagnostic et traitement.
  • OBJECTIVES: Parapharyngeal space tumors are rare and usually benign.
  • We report our experience in managing these neoplasms.
  • Two points are developed more fully: the correlation between imaging and surgical observation and the reliability of the cervical approach.
  • Nine patients were included, all treated surgically with a cervical approach without parotidectomy.
  • They were benign in all cases (five salivary tumors and four schwannomas).
  • CONCLUSION: The cervical approach is safe and allows the surgical excision of retrostyloid and prestyloid tumors, independent of the deep lobe of the parotid gland.
  • Large tumor (8cm in our study) excision can be done with few complications.
  • [MeSH-major] Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18678362.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


68. Richter C, Baetje M, Bischof A, Makovitzky J, Richter DU, Gerber B, Briese V: Expression of the glycodelin A gene and the detection of its protein in tissues and serum of ovarian carcinoma patients. Anticancer Res; 2007 Jul-Aug;27(4A):2023-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glycodelin A (GdA), also known as placental protein 14 (PP14), has been detected in endometrial, cervical and ovarian carcinoma cells.
  • MATERIALS AND METHODS: We investigated serum, tissue and cyst fluid samples of patients with an ovarian carcinoma in contrast to patients with benign and malignant diseases such as uterine myoma, endometriosis, cervical, uterine and breast cancer, and metastases of bladder and colon carcinoma.
  • CONCLUSION: These results indicate that determination of GdA is not sensitive or specific enough for use as a tumour marker.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression. Glycoproteins / biosynthesis. Ovarian Neoplasms / diagnosis. Pregnancy Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649816.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger
  •  go-up   go-down


69. Liu K, Ouyang H, Zhou CW, Tao H: [Preliminary application of diffusion-weighted imaging with 3.0 T magnetic resonance scanner for nasopharyngeal carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):200-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four groups of b value (600, 800, 1000 and 1200) were applied.
  • The apparent diffusion coefficients (ADC) between the primary tumor of NPC and the metastatic lymph nodes were compared in each group.
  • ADC between the metastatic lymph nodes and benign nodes were also compared.
  • RESULTS: Although the mean ADC were not significantly different between NPC and those of metastatic cervical lymph nodes in each group, the mean ADC of the metastatic lymph nodes were significantly lower than those of benign nodes (P<0.05).
  • CONCLUSION: DWI is helpful in the diagnosis of primary lesions and their lymph node metastases of NPC.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Nasopharyngeal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450553.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Nasopharyngeal carcinoma
  •  go-up   go-down


70. Qu JQ, Gao X, Hou WP, Teng H, Tong XD, Wang SM, Xu SG: [Video-assisted thoracic surgery: clinical experience among 1264 patients]. Zhonghua Yi Xue Za Zhi; 2006 Sep 5;86(33):2309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From December 1993 to December 2005 1264 patients, 894 males and 370 females, aged 38.9 +/- 12.0, underwent VATS, including bullectomy in 622 cases, resection of mediastinal tumor or cyst in 119 cases, resection of esophageal diseases in 107 cases, lobectomy or wedge-shaped lung resection in 215 cases, lung volume reduction surgery (LVRS) in 17 cases, treatment of thoracic injury in 28 cases, treatment of other thoracic diseases in 72 cases, and biopsy in 84 cases.
  • For the resection of esophageal carcinoma VATS was conducted via the right approach, the esophagus was dissociated, the lymph nodes were resected, upper-abdominal incision was made, the stomach was dissociated and drawn up to the neck region, a cervical incision was made to anastomose the stomach and the residue of esophagus.
  • CONCLUSION: Spontaneous pneumothorax and some benign thoracic diseases are the major indications of VATS; however, great care should be expended to decide to treat malignant diseases by VATS.

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156622.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Conesa-Zamora P, Doménech-Peris A, Ortiz-Reina S, Orantes-Casado FJ, Acosta-Ortega J, García-Solano J, Pérez-Guillermo M: Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol; 2009 Feb;62(2):159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix.
  • AIMS: Considering the sparse information about the clinical utility of the novel immunohistochemical marker ProEx C in histological sections, a decision was taken to study the pattern of ProEx C expression in normal/benign cervical epithelium (N/B), low-grade squamous intraepithelial lesion (LGSIL) and high-grade squamous intraepithelial lesion (HGSIL), as well as the association of ProEx C expression with human papillomavirus (HPV) genotypes.
  • METHODS: 100 cervical samples, including 21 N/B cervices, 16 LGSILs, 61 HGSILs and two cervical invasive carcinomas, were obtained from conisation and hysterectomy.
  • RESULTS: ProEx C-positive expression in more than the lower third of the epithelium was observed in 14.3% of N/B, 62.5% of LGSIL and 90.2% of HGSIL.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cervix Uteri / metabolism. Female. Genotype. Human papillomavirus 16 / isolation & purification. Humans. Immunoenzyme Techniques / methods. Indicators and Reagents. Papillomaviridae / classification. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Precancerous Conditions / virology. Tissue Array Analysis


72. Rodrigues LM, Nicolau RJ, Puertas EB, Milani C: Vertebrectomy of giant cell tumor with vertebral artery embolization: case report. J Pediatr Orthop B; 2009 Mar;18(2):99-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vertebrectomy of giant cell tumor with vertebral artery embolization: case report.
  • Giant cell tumors (GCT) are rare in the cervical spine in adolescent children.
  • This tumor is histologically benign, but there is a high recurrence rate.
  • Although surgical resection of GCT arising in the cervical spine is commonly regarded as recommended treatment method, it is still a challenge to achieve satisfactory results.
  • The authors describe a case of a patient of adolescent age with a GCT in the cervical spine.
  • It was necessary to study the embolization of the vertebral artery to planning the vertebrectomy surgery for resection of the entire tumor to avoid recurrence.
  • The resection of the tumor was carried out by combined access (anteriorly and posteriorly) and was stabilized with plate, posterior lateral mass screws, and autologous iliac crest graft.
  • [MeSH-major] Cervical Vertebrae / surgery. Embolization, Therapeutic / methods. Giant Cell Tumor of Bone / therapy. Spinal Neoplasms / therapy. Vertebral Artery

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276993.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Wang V, Chou D: Anterior C1-2 osteochondroma presenting with dysphagia and sleep apnea. J Clin Neurosci; 2009 Apr;16(4):581-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spinal osteochondromas are rare, benign tumors of the bone.
  • Most spinal osteochondromas occur in the posterior cervical spine and can cause myelopathy or radiculopathy.
  • Osteochondromas of the anterior cervical spine that cause respiratory or swallowing symptoms are rare.
  • The patient underwent resection of the tumor via a left anterior transcervical approach to the spine.
  • [MeSH-major] Cervical Vertebrae / pathology. Deglutition Disorders / etiology. Sleep Apnea Syndromes / etiology. Spinal Osteochondrosis / complications. Spinal Osteochondrosis / pathology


74. Munro EG, Jain M, Oliva E, Kamal N, Lele SM, Lynch MP, Guo L, Fu K, Sharma P, Remmenga S, Growdon WB, Davis JS, Rueda BR, Batra SK: Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance. Int J Gynecol Pathol; 2009 Mar;28(2):127-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.
  • MUC4 is a transmembrane glycoprotein more highly expressed in cervical dysplasia than benign cervical epithelium.
  • We sought to determine whether MUC4 expression differs between benign and malignant cervical tissue.
  • Fifty-eight patients with benign, dysplastic, or malignant cervical pathology were identified retrospectively, and representative sections were stained with a mouse monoclonal anti-MUC4 antibody.
  • Semiquantitative analysis was performed on benign, dysplastic, and malignant regions by scoring staining intensity (0: negative, 1: weak, 2: moderate, and 3: strong) and distribution (focal <10%, multifocal=10%-60%, diffuse > or =60%).
  • In samples with benign glycogenated squamous epithelium, only the parabasal cells had MUC4 staining, and 48.5% had an intensity of 2 or 3.
  • Cervical intraepithelial neoplasia (CIN) 1 samples had variable staining with an intensity similar to glycogenated squamous epithelium but distribution similar to squamous metaplasia.
  • In contrast, no differences in staining were observed between benign endocervical glands, adenocarcinoma in situ, and invasive adenocarcinoma.
  • These expression patterns suggest that MUC4 is a lineage marker in benign cervical tissue that may have aberrant expression in squamous dysplasia and carcinoma.
  • Further studies may elucidate the role of MUC4 in the development of squamous cell cervical cancer.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7524-32 [12386815.001]
  • [Cites] Bioessays. 2003 Jan;25(1):66-71 [12508284.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):13-7 [14668544.001]
  • [Cites] Gut. 2000 Dec;47(6):753-61 [11076872.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1192-206 [11578969.001]
  • [Cites] Hum Pathol. 2001 Nov;32(11):1197-202 [11727258.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):849-55 [14675323.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):209-14 [15047238.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):637-9 [7905784.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5263-6 [10026131.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):325-33 [10024507.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):354-8 [10366459.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Front Biosci. 2006;11:2071-6 [16720293.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1510-5 [17090193.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Cancer Lett. 2007 Jun 28;251(2):247-57 [17210225.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • (PMID = 19188823.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS228381; NLM/ PMC2932462
  •  go-up   go-down


75. Na JH, Kim HS, Eoh W, Kim JH, Kim JS, Kim ES: Spinal cord hemangioblastoma : diagnosis and clinical outcome after surgical treatment. J Korean Neurosurg Soc; 2007 Dec;42(6):436-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord hemangioblastoma : diagnosis and clinical outcome after surgical treatment.
  • OBJECTIVE: Spinal cord hemangioblastoma is an uncommon vascular neoplasm with a benign nature and is associated with von Hippel-Lindau (VHL) disease in 20-30% of patients.
  • Magnetic resonance imaging (MRI) of the complete neuraxis was done in all cases and VHL mutation analysis was performed in three cases for a definite diagnosis.
  • RESULTS: Six patients had intramedullary tumor, and the remaining patients had intradural extramedullary lesions.
  • Tumors were located in the cervical cord in five cases and in the thoracic cord in four cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2005 Jun;56(6):1215-21; discussion 1221 [15918937.001]
  • [Cites] Am J Med. 1964 Apr;36:595-617 [14142412.001]
  • [Cites] J Neurosurg. 1952 Sep;9(5):484-94 [12981570.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):333-9; discussion 339-40 [10352742.001]
  • [Cites] Hum Mutat. 1998;12(6):417-23 [9829911.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] J Intern Med. 1998 Jun;243(6):547-53 [9681857.001]
  • [Cites] Cancer Treat Res. 1996;88:13-39 [9239471.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Neurosurg Rev. 1996;19(3):147-51 [8875501.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] Neurosurgery. 1994 Nov;35(5):865-73; discussion 873 [7838335.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):671-5; discussion 675-6 [7808610.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):321-7; discussion 327-8 [11504107.001]
  • [Cites] Genomics. 2000 May 1;65(3):253-65 [10857749.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):1-22; discussion 23-4 [10809480.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Neurosurg Rev. 1993;16(3):205-9 [8272209.001]
  • [Cites] JAMA. 1992 Mar 4;267(9):1226-31 [1347089.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):898-901 [1431953.001]
  • [Cites] Neurology. 1991 Jan;41(1):41-6 [1985294.001]
  • [Cites] Q J Med. 1990 Nov;77(283):1151-63 [2274658.001]
  • [Cites] AJNR Am J Neuroradiol. 1985 Mar-Apr;6(2):287-9 [3920885.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):699-707; discussion 708 [2586724.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;43:9-12 [3213664.001]
  • [Cites] J Neurosurg. 1988 Apr;68(4):550-3 [3351582.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):269-75 [3945908.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):523-32 [2319309.001]
  • [Cites] Neurochirurgie. 1975 Jun;21 Suppl 1:1-136 [1103000.001]
  • [Cites] Surg Neurol. 1976 Sep;(3):141-8 [986698.001]
  • [Cites] Arch Neurol. 1976 Jun;33(6):435-41 [945725.001]
  • [Cites] Hum Mutat. 2004 Sep;24(3):215-24 [15300849.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Acta Neurochir (Wien). 2001 Sep;143(9):893-6 [11685621.001]
  • (PMID = 19096585.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588179
  • [Keywords] NOTNLM ; Hemangioblastoma / Mutation analysis / Von Hippel-Lindau disease
  •  go-up   go-down


76. Hunter CL, Pacione D, Hornyak M, Murali R: Giant-cell tumors of the cervical spine: case report. Neurosurgery; 2006 Nov;59(5):E1142-3; discussion E1143
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell tumors of the cervical spine: case report.
  • OBJECTIVE: Giant-cell tumors of bone are rare, benign neoplasms that occur infrequently in the spine above the sacrum, and their presence in the cervical vertebrae is even more exceptional.
  • Although complete en bloc surgical resection is difficult in the cervical spine, treatment with adjuvant radiotherapy has been considered controversial because of a small risk of malignant transformation.
  • The authors report two cases of giant-cell tumors in the cervical vertebrae that were treated successfully with surgical excision and postoperative radiation as well as long-term follow-up.
  • INTERVENTION: In one case, the tumor was treated by anterior resection, then by laminectomy and instrumented fusion, and finally by adjuvant postoperative radiotherapy.
  • However, the tumor recurred, and, after several surgical procedures, external beam radiotherapy was administered.
  • The patients have been followed for 17 and 11 years, respectively, with no evidence of tumor recurrence.
  • However, complete resection is often not a feasible option for tumors in the cervical spine because of involvement of critical neurovascular structures.
  • [MeSH-major] Cervical Vertebrae / surgery. Giant Cell Tumor of Bone / diagnosis. Giant Cell Tumor of Bone / surgery. Laminectomy / methods. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery. Thoracic Vertebrae / surgery

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143206.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. De Cerchio L, Contratti F, Fraioli MF: Dorsal dumb-bell melanotic schwannoma operated on by posterior and anterior approach: case report and a review of the literature. Eur Spine J; 2006 Oct;15 Suppl 5:664-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The schwannomas are benign tumors originating from Schwann cells which constitute the nerve sheath.
  • The patient underwent a surgical procedure for en bloc total removal of the mass by a posterior and anterior approach.
  • Histopathological examination revealed the diagnosis of melanotic schwannoma.
  • As the total removal of the melanotic neurinomas is mandatory to prevent possible malignant transformation of the tumor recurrence or regrowth, we believe that the posterior and trans-thoracic approach are the most suitable one for the dorsal dumb-bell schwannoma.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Neurosurgical Procedures / methods. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1988 Sep;16(10):1199-205 [3060751.001]
  • [Cites] Neurochirurgie. 1988;34(3):210-7 [3054600.001]
  • [Cites] Eur J Radiol. 1990 Sep-Oct;11(2):138-42 [2253635.001]
  • [Cites] Am J Clin Pathol. 1991 Apr;95(4):484-9 [2014773.001]
  • [Cites] Ann Pathol. 1993;13(3):184-7 [8397544.001]
  • [Cites] Arch Anat Cytol Pathol. 1994;42(1):46-53 [8074546.001]
  • [Cites] Tumori. 1995 May-Jun;81(3):208-12 [7571031.001]
  • [Cites] Pathol Res Pract. 1996 Nov;192(11):1142-6; discussion 1147 [9122034.001]
  • [Cites] Cesk Patol. 1997 Nov;33(4):141-5 [9501653.001]
  • [Cites] Semin Diagn Pathol. 1998 Aug;15(3):216-24 [9711672.001]
  • [Cites] Diagn Cytopathol. 1998 Oct;19(4):298-302 [9784997.001]
  • [Cites] J Neurosurg Sci. 1998 Dec;42(4):245-9 [10404754.001]
  • [Cites] Am J Med Genet. 1999 Sep 3;86(1):62-5 [10440831.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):453-4, 458-9 [15605993.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):72-8 [15483077.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):151-6 [15690131.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Mar;262(3):182-5 [15133690.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):501-8 [15992699.001]
  • [Cites] Chin Med J (Engl). 2005 Sep 5;118(17):1451-61 [16157048.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(3):160-3 [7574916.001]
  • [Cites] Histopathology. 1999 Dec;35(6):558-66 [10583580.001]
  • [Cites] J Neurol. 1999 Nov;246(11):1100-2 [10631648.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):241-5 [10763702.001]
  • [Cites] Neuroradiology. 2000 Apr;42(4):275-9 [10872172.001]
  • [Cites] Neuroradiology. 2000 Jun;42(6):458-61 [10929310.001]
  • [Cites] Rozhl Chir. 2001 Nov;80(11):572-4 [11794055.001]
  • [Cites] Neurochirurgie. 2003 Mar;49(1):31-8 [12736578.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):925-34 [12792904.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):249-54 [15332329.001]
  • [Cites] Wien Klin Wochenschr. 2004;116 Suppl 2:93-6 [15506323.001]
  • [Cites] J Neurosurg. 1974 Aug;41(2):187-92 [4841875.001]
  • [Cites] Surg Neurol. 1975 Feb;3(2):79-81 [1118806.001]
  • [Cites] Neurosurgery. 1978 Jan-Feb;2(1):47-51 [683481.001]
  • [Cites] Thorax. 1979 Apr;34(2):243-6 [483192.001]
  • [Cites] Am J Surg Pathol. 1979 Feb;3(1):3-10 [534381.001]
  • [Cites] Cancer. 1980 Jul 15;46(2):391-7 [7388777.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):718-24 [7397634.001]
  • [Cites] Neurosurgery. 1982 Jul;11(1 Pt 1):57-60 [7110568.001]
  • [Cites] Appl Pathol. 1984;2(2):110-5 [6537255.001]
  • [Cites] Ultrastruct Pathol. 1985;9(1-2):123-9 [4089993.001]
  • [Cites] Arch Anat Cytol Pathol. 1987;35(2):76-81 [3632063.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):174-83 [3289725.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):206-22 [2305928.001]
  • (PMID = 16947016.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC1602204
  •  go-up   go-down


78. Pham NS, Poirier B, Fuller SC, Dublin AB, Tollefson TT: Pediatric lipoblastoma in the head and neck: a systematic review of 48 reported cases. Int J Pediatr Otorhinolaryngol; 2010 Jul;74(7):723-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present an additional case and review of the available literature on this rare neoplasm.
  • MEDLINE was searched for the terms "neonatal lipoblastoma", "lipoblastomatosis", and "benign lipoblastoma".
  • This tumor presents a clinical challenge and should be considered in infants presenting with a cervical mass.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lipoma / pathology
  • [MeSH-minor] Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Respiratory Distress Syndrome, Newborn / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20472310.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


79. Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M: [Urine diacetylspermine as a novel tumor marker]. Rinsho Byori; 2005 Feb;53(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urine diacetylspermine as a novel tumor marker].
  • A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies.
  • Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia.
  • The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%.
  • These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / urine. Genital Neoplasms, Female / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796046.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  • [Number-of-references] 6
  •  go-up   go-down


80. Arafa M, Boniver J, Delvenne P: Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):422-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study.
  • The aim of this study was to evaluate the usefulness of a panel of biomarkers in the characterization of human papillomavirus (HPV)-induced cervical lesions.
  • Misinterpretation especially for benign mimics results in a significant diagnostic disagreement.
  • For these reasons, a continuous effort is still needed to discover surrogate markers, which could support the final diagnosis.
  • Archival biopsies of normal ectocervical and endocervical tissues, squamous metaplasia, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, adenocarcinoma in situ, and adenocarcinoma were retrieved to perform a tissue microarray (TMA).
  • In conclusion, using a panel of cervical biomarkers improves the final reporting of various HPV-induced epithelial lesions.


81. Kohrenhagen N, Voelker HU, Schmidt M, Kapp M, Krockenberger M, Frambach T, Dietl J, Kammerer U: Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. J Obstet Gynaecol Res; 2008 Jun;34(3):293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia.
  • AIM: It is supposed that increased glycolysis is crucial for the energy supply during tumor progression.
  • Unfortunately, the relevance of glycolysis in cervical neoplasia is unknown, but what is certain is the fact that cervical cancer shows a high expression of glucose membrane transporters, which are necessary for glucose uptake as an energy source.
  • Thus, we were interested in their expression in cervical tissue.
  • METHODS: We examined the expression of TKTL1 and p-Akt in 80 formalin-fixed, paraffin-embedded cervical specimens: 20 benign cervical tissues, 20 low-grade squamous intraepithelial lesions, 20 high-grade intraepithelial lesions, and 20 invasive squamous cell carcinomas (ISCC).
  • RESULTS: Immunhistochemical analyses revealed that the intensity of the expression of TKTL1 and p-Akt increases significantly with an increase in the histopathological grade of cervical tissues.
  • CONCLUSION: The results suggest that both TKTL1 and p-Akt play an important role in the progression of cervical neoplasia, which may be due to their impact on glycolysis.
  • [MeSH-major] Proto-Oncogene Proteins c-akt / metabolism. Transketolase / metabolism. Uterine Cervical Neoplasms / chemistry
  • [MeSH-minor] Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / chemistry. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / chemistry. Female. Glycolysis. Humans. Immunohistochemistry. Paraffin Embedding


82. Han XY, Xiang Y, Guo LN, Sheng K, Wan XR, Huang HF, Pan LY: [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
  • OBJECTIVE: To investigate the clinicopathologic features, diagnosis, treatment and prognosis of uterine mullerian adenosarcoma.
  • METHODS: The clinicopathological data of 9 cases of uterine mullerian adenosarcoma in PUMC hospital from January 2003 to February 2009 were retrospectively analyzed.
  • RESULTS: There were 6 uterine endometrial adenosarcomas and 3 cervical adenosarcomas.
  • Physical examination showed cervical/vaginal mass, enlarged uterus or pelvic mass.
  • The adenosarcoma was characterized by benign or atypical-appearing neoplastic glands within a sarcomatous stroma.
  • During the follow-up, 2 cases of uterine endometrial adenosarcoma recurred.
  • The other one recurred 2 years after local excision of the tumor in the uterine cavity and she remained healthy since hysterectomy.
  • CONCLUSION: Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs.
  • The diagnosis depends on pathomorphologic examination.
  • [MeSH-major] Endometrial Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenosarcoma / drug therapy. Adenosarcoma / pathology. Adenosarcoma / surgery. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Ifosfamide / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Uterine Neoplasms / drug therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211067.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; Adenosarcoma of the uterus; ICE protocol 1
  •  go-up   go-down


83. Lee JW, Choi JJ, Lee KM, Choi CH, Kim TJ, Lee JH, Kim BG, Ahn G, Song SY, Bae DS: eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol; 2005 Nov;36(11):1197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] eIF-4E expression is associated with histopathologic grades in cervical neoplasia.
  • The expression is known to be elevated in several carcinomas as compared with normal tissues and benign lesions.
  • In the present study, we undertook to determine whether eIF-4E expression is associated with progression in cervical neoplasia. eIF-4E expression was evaluated by immunohistochemistry in 88 formalin-fixed, paraffin-embedded cervical tissues; 10 normal cervical specimens; 19 low-grade cervical intraepithelial neoplasias (CINs); 19 high-grade CINs; and 40 invasive squamous cell carcinomas (ISCCs).
  • In addition, eIF-4E expression was evaluated at the RNA level in fresh frozen cervical carcinoma tissues by real-time quantitative reverse transcriptase polymerase chain reaction.
  • Immunohistochemical staining showed that eIF-4E expression was undetectable in most normal cervical squamous epithelial tissues (90%), but variable staining was observed in the basal layer of all normal endocervical glands. eIF-4E expression, which was mainly observed as cytoplasmic staining, gradually increased in accordance with histopathologic grade in the order low-grade CIN < high-grade CIN < ISCC (P < .001) and, in particular, was strongly detected in all ISCC cases.
  • Furthermore, real-time quantitative reverse transcriptase polymerase chain reaction revealed that eIF-4E expression in tumor was significantly enhanced versus normal cervical tissues (P = .037).
  • These results suggest that eIF-4E may play a significant role in tumor progression of cervical neoplasia and may represent useful markers for malignant transformation of cervical squamous cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Eukaryotic Initiation Factor-4E / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction


84. Park KJ, Soslow RA, Sonoda Y, Barakat RR, Abu-Rustum NR: Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. Gynecol Oncol; 2008 Sep;110(3):316-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.
  • OBJECTIVE: To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions.
  • An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al. was also applied to the frozen and permanent section slides and compared to the final diagnosis.
  • RESULTS: There was 84% concordance between the frozen-section and final diagnosis using histology alone, vs. 95% concordance using the Ioffe scoring system.
  • One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin, which in retrospect, was a benign lesion and was correctly classified using the Ioffe system.
  • CONCLUSION: Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions, especially during frozen-section evaluation of the trachelectomy.
  • Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system, like that proposed by Ioffe et al., can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Frozen Sections. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Retrospective Studies. Severity of Illness Index. Tumor Stem Cell Assay


85. Ayaru L, Stoeber K, Webster GJ, Hatfield AR, Wollenschlaeger A, Okoturo O, Rashid M, Williams G, Pereira SP: Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer; 2008 May 06;98(9):1548-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates.
  • We have previously shown that minichromosome maintenance (MCM) replication proteins (Mcm2-7) are markers of dysplasia and have utilised these novel biomarkers of growth for the diagnosis of cervical and bladder cancer.
  • In 30 tissue specimens from patients with malignant/benign biliary strictures, we studied Mcm2 and -5 expression by immunohistochemistry.
  • In benign biliary strictures, Mcm2 and -5 protein expression was confined to the basal epithelial proliferative compartment - in contrast to malignant strictures where expression was seen in all tissue layers.
  • The percentage of nuclei positive for Mcm2 was higher in malignant tissue (median 76.5%, range 42-92%) than in benign tissue (median 5%, range 0-33%) (P<0.0005), with similar results for Mcm5.
  • [MeSH-major] Bile / chemistry. Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / analysis. Cell Cycle Proteins / analysis. Nuclear Proteins / analysis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Trends Cell Biol. 2002 Feb;12(2):72-8 [11849970.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1071-9 [12122098.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):552-61 [12297773.001]
  • [Cites] EMBO J. 1998 Dec 15;17(24):7219-29 [9857179.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:20-4 [10466756.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] Gut. 2004 Dec;53(12):1727-9 [15542504.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):78-80 [16377320.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2006 Feb;3(2):74-5 [16456571.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):720-30 [12397282.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):45-51 [14687140.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1464-9 [15307861.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):565-72 [8674929.001]
  • [Cites] Gut. 1997 May;40(5):671-7 [9203949.001]
  • [Cites] Biochim Biophys Acta. 1998 Jun 16;1398(2):113-36 [9689912.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):383-90 [10744806.001]
  • (PMID = 18414413.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801588; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2391096
  •  go-up   go-down


86. Beseoglu K, Knobbe CB, Reifenberger G, Steiger HJ, Stummer W: Supratentorial meningeal melanocytoma mimicking a convexity meningioma. Acta Neurochir (Wien); 2006 Apr;148(4):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Meningeal melanocytomas are rare benign neuro-ectodermal tumors arising from melanocytic cells in the leptomeninges.
  • These leptomeningeal melanocytes are found at highest density underneath the brain stem and along the upper cervical spinal cord.
  • INTERVENTION: Tumor control to date was achieved by surgery of the large lesion and radiosurgery of the small lesion.
  • CONCLUSION: Complete tumor resection may be advantageous and second or recurrent lesions may be managed by repeat surgery or stereotactic radiosurgery.
  • [MeSH-major] Melanocytes / pathology. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Neoplasms, Multiple Primary / pathology. Nevus / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors / prevention & control. Humans. Magnetic Resonance Imaging. Male. Meninges / pathology. Middle Aged. Neurosurgical Procedures. Parietal Lobe / pathology. Parietal Lobe / surgery. Radiosurgery. Rare Diseases. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391879.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


87. Novosel T, Ritter HE, Gupta M, Harvey A, Mitchell J, Berber E, Siperstein A, Milas M: Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. Surgery; 2009 Dec;146(6):1081-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Circulating thyroid cancer cells detected by peripheral blood thyroid-stimulating hormone receptor (TSHR) mRNA have demonstrated usefulness for thyroid cancer diagnosis and long-term surveillance.
  • METHODS: We compared clinical characteristics of 37 patients with papillary thyroid microcarcinomas (PTMC; tumor size </=1 cm) having undetectable (-) versus detectable (+)TSHR mRNA.
  • RESULTS: 59 Of the PTMC patients, 59% had (+)TSHR mRNA levels, similar to those with tumors >1 cm (72%; P = NS) and distinctly higher than false (+) rates in benign goiters (15%; P < .001).
  • Mean tumor size (5 mm) and multifocality rates (45%) were similar in both mRNA groups.
  • Of the PTMC patients, 35% had concurrent cervical nodal metastases, which occurred more frequently with tumors >/=5 mm (P = .04) and with (+)TSHR mRNA in pre-operatively known PTMC (P < .05).
  • [MeSH-major] Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Neoplastic Cells, Circulating / pathology. Thyroid Neoplasms / blood. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Male. Middle Aged. Prospective Studies. RNA, Messenger / blood. RNA, Messenger / genetics. RNA, Neoplasm / blood. RNA, Neoplasm / genetics. Receptors, Thyrotropin / genetics. Young Adult


88. Bergoeing R M, Mertens M R, Valdés E F, Krämer Sch A, Alvarez Z M, Bertin C P, Sagüés C R, Orellana U E, Galindo A H, Vergara G J, Valdebenito C M: [Endovascular treatment of superior vena cava syndrome]. Rev Med Chil; 2006 Jul;134(7):827-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tratamiento endovascular del síndrome de vena cava superior.
  • Common clinical findings are headache and cervical, facial and upper limb edema.
  • Six had a benign obstruction due to the presence of a chemotherapy catheter located in the superior vena cava, one had obstruction secondary to radiation therapy and one a tumor compression of the superior vena cava.
  • During follow up, only one patient had symptoms related to vena cava obstruction and three died due to their malignant tumor.
  • [MeSH-minor] Adult. Aged. Catheterization / adverse effects. Female. Humans. Male. Middle Aged. Neoplasms / complications. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Superior vena cava syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130964.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


89. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • In some areas endometrial glands of adenomyosis were replaced by benign-looking mucinous metaplasia.
  • The uterine cervix showed no abnormalities.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • This case provokes a discussion on diagnostic and management strategy, and histogenesis of mucinous neoplasm of the endometrium.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


90. Setzer M, Vatter H, Marquardt G, Seifert V, Vrionis FD: Management of spinal meningiomas: surgical results and a review of the literature. Neurosurg Focus; 2007;23(4):E14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cox proportional hazards regression analysis showed three significant predictor variables for recurrence: invasion of the arachnoid/pia (p < 0.05; hazard ratio [HR] 1.8, 95% CI 1.2-3.6), Simpson resection grade (p < 0.012, HR 6.8, 95% CI 1.5-3.0), and histological tumor grade (Grade I; p < 0.001, HR 0.001-0.17).
  • CONCLUSIONS: Because of the excellent outcome of surgery for benign spinal meningiomas and the association between duration of symptoms and neurological compromise with a poor functional outcome, early operation is the treatment of choice.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cervical Vertebrae. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Recovery of Function. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961038.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


91. Ferlito A, Devaney KO, Rinaldo A: Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor. Acta Otolaryngol; 2006 Mar;126(3):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor.
  • The concept of a carcinoid tumor in the gastrointestinal tract and lung is well established; less often, patients develop carcinoid tumors in the head and neck region.
  • Middle ear carcinoids have previously been approached as benign entities, lacking any capacity for metastasizing.
  • A critical review of the literature, however, disclosed a small number of cases in which middle ear carcinoid tumors have given rise to regional (cervical node) metastases.
  • [MeSH-major] Carcinoid Tumor / secondary. Ear Neoplasms / pathology. Ear, Middle. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618645.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 21
  •  go-up   go-down


92. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
  • Adenocarcinoma in situ of the uterine cervix remains a diagnostic challenge in a small proportion of cases.
  • This suggests a need for biomarker that may be of help in establishing the diagnosis.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • In addition to benign endocervical epithelium, 19 of these 23 control cases also showed focal tubal metaplasia.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Cervix Uteri / metabolism. Cervix Uteri / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged


93. Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, Ortiz-Reina S, Sahuquillo-Frías L, Acosta-Ortega J, García-Solano J, Pérez-Guillermo M: Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol; 2009 Sep;132(3):378-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study.
  • In-depth study of cell cycle proteins and human papillomavirus (HPV) genotyping can provide useful information about the malignant potential of precursor lesions of cervical carcinoma (CC).
  • Immunostaining of cell cycle-related proteins (p16, cyclin D1, Ki-67, p53, and ProEx C) was evaluated using tissue microarrays, and HPV genotypes were identified in 144 cervical tissue specimens encompassing normal or benign epithelial lesions, low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), and CC.
  • Immunohistochemical assessment of cell cycle proteins may help to distinguish normal and benign conditions of the cervix from precursor lesions of CC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Cycle / physiology. Papillomavirus Infections / metabolism. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cyclin D1 / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Tissue Array Analysis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687314.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


94. Kinoshita S, Kakizaki H, Iwaki M, Hara K: [Two cases of dermolipoma]. Nippon Ganka Gakkai Zasshi; 2007 Dec;111(12):965-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dermolipoma is an uncommon benign tumor, congenitally occurring on the conjunctiva, and may be present at other sites.
  • The appearance of dermolipoma closely resembles orbital fat prolapse and limbal dermoid, and therefore it is necessary to take this into account in diagnosis.
  • Another case, an 8-year-old female patient, was referred for the treatment of a bulbar conjunctival tumor in her left eye.
  • In both cases, dermolipoma was suspected because the tumor did not show in the limbus and it did not change in size even when the eyeball was pressed.
  • There was no external ear anomaly, facial dissymmetry, or cervical abnormality.
  • CONCLUSIONS: If the special features of dermolipoma are understood, it is easy to distinguish this tumor from other disorders.
  • [MeSH-minor] Child. Conjunctival Neoplasms / congenital. Conjunctival Neoplasms / surgery. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186219.001).
  • [ISSN] 0029-0203
  • [Journal-full-title] Nippon Ganka Gakkai zasshi
  • [ISO-abbreviation] Nippon Ganka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Bellanger S, Blachon S, Mechali F, Bonne-Andrea C, Thierry F: High-risk but not low-risk HPV E2 proteins bind to the APC activators Cdh1 and Cdc20 and cause genomic instability. Cell Cycle; 2005 Nov;4(11):1608-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses (HPVs) from the high-risk group are associated with cervical cancer, in contrast to HPVs from the low-risk group which are associated with benign lesions of the genital tract.
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cdc20 Proteins. Cell Line, Tumor. Human papillomavirus 6 / metabolism. Humans. Protein Binding / genetics. Risk Factors

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222116.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Cdc20 Proteins; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / E2 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / oncogene protein E2, Human papillomavirus type 18; 156288-95-8 / CDC20 protein, human; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


96. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn; 2009 Sep;9(6):555-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic screening, such as pap smears for detection of cervical cancer, is not feasible for these diseases given difficulty with access to the tissue.
  • Thus, a serum- screening test using a biomarker or panel of biomarkers would be useful to aid in cancer diagnosis, detection of recurrence and as a means to monitor response to therapy.
  • Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 Jun;19(6):847-53 [16607372.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1513-22 [17354232.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):813-21 [17765190.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4159-61 [17698803.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2647-55 [18451228.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Mol Graph Model. 1999 Apr;17(2):106-13, 134-6 [10680116.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):699-708 [10793106.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):795-9 [17845837.001]
  • [Cites] Gynecol Oncol. 2008 Aug;110(2):196-201 [18495222.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):374-82 [18584856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7 [18768519.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6 [19134334.001]
  • [Cites] Cancer. 2009 Feb 15;115(4):812-22 [19127552.001]
  • [Cites] Br J Cancer. 2009 Apr 21;100(8):1315-9 [19337252.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):534-40 [11169935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1824-30 [11747321.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):36-42 [11748973.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2768-73 [11965550.001]
  • [Cites] J Endocrinol. 2002 May;173(2):219-38 [12010630.001]
  • [Cites] Recent Prog Horm Res. 2002;57:435-55 [12017556.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1765-8 [12168866.001]
  • [Cites] Biochem J. 2002 Nov 15;368(Pt 1):233-42 [12206714.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3919-26 [15173101.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):567-71 [15297205.001]
  • [Cites] Eur Cytokine Netw. 2004 Apr-Jun;15(2):99-104 [15319167.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Am J Clin Pathol. 1983 Jan;79(1):98-104 [6336888.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Int J Gynecol Pathol. 1983;2(3):275-85 [6196309.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Obstet Gynecol. 1985 Apr;65(4):568-72 [3982731.001]
  • [Cites] Clin Chim Acta. 1986 Mar 16;155(2):163-5 [3009058.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):307-12 [3164697.001]
  • [Cites] Br J Obstet Gynaecol. 1989 Dec;96(12):1395-9 [2620051.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1917-25 [2698807.001]
  • [Cites] Int J Androl. 1990 Apr;13(2):155-67 [1693137.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):14791-5 [2394696.001]
  • [Cites] Acta Obstet Gynecol Scand. 1990;69(5):423-9 [2270768.001]
  • [Cites] Biol Reprod. 1991 Aug;45(2):350-7 [1686187.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1379-81 [1442994.001]
  • [Cites] Obstet Gynecol. 1995 Aug;86(2):259-64 [7617357.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6172-80 [8521410.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):320-8 [9408747.001]
  • [Cites] J Endocrinol. 1998 Jul;158(1):137-44 [9713335.001]
  • [Cites] Curr Opin Oncol. 1998 Sep;10(5):439-46 [9800115.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):32-7 [9889026.001]
  • [Cites] Biochem J. 1999 Jun 15;340 ( Pt 3):569-77 [10359639.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:380-9 [15650263.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2162-9 [15781627.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):383-9 [15950183.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):447-61 [16126262.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):45-51 [16382112.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):589-98 [16369985.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Lancet Oncol. 2006 Feb;7(2):167-74 [16455481.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):561-4 [16271748.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7 [16515561.001]
  • (PMID = 19732003.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / R01 HD041577; United States / NICHD NIH HHS / HD / R01 HD041577-06; United States / NICHD NIH HHS / HD / R01 HD 41577
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  • [Number-of-references] 80
  • [Other-IDs] NLM/ NIHMS145815; NLM/ PMC3273415
  •  go-up   go-down


97. Harzallah L, Zouari L, Ben Chérifa L, Harzallah F, Sriha B, Bakir D, Kraiem Ch: [Adrenal gland hemangioma: a case report]. Ann Endocrinol (Paris); 2006 Dec;67(6):624-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioma is a benign vascular tumor composed of angioblastic cells.
  • We report a case of adrenal gland hemangioma diagnosed in a 55-year-old woman who presented a cervical neoplasm.
  • The non-specific imaging features, the tumor size and the clinical context led to mandatory surgical resection.
  • The pathological examination established the diagnosis of adrenal gland hemangioma.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Hemangioma / radiography
  • [MeSH-minor] Female. Humans. Middle Aged. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194976.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


98. Asilian A, Tamizifar B: Aggressive and neglected basal cell carcinoma. Dermatol Surg; 2005 Nov;31(11 Pt 1):1468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cutaneous malignancy and usually has a benign coarse.
  • Rarely, examples of aggressive and neglected types of this tumor are seen.
  • He also had skull bone destruction, osteomyelitis, mastoiditis, cranial nerve paralysis, and radiographic features of the skull base and upper cervical soft tissue involvement.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416624.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Walid MS, Heaton RL: Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure. Ger Med Sci; 2010;8:Doc26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of a cervical lipoleiomyoma with an incidentally discovered ovarian granulosa cell tumor - imaging and minimal-invasive surgical procedure.
  • Uterine lipoleiomyomas are rare benign tumors that mostly affect the uterine corpus.
  • We are reporting the imaging and operative procedure of a very rare case of a large lipoleiomyoma of the uterine cervix combined with an occult adult ovarian granulosa cell tumor.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Leiomyoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):239-42 [16810060.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):439-40 [11874076.001]
  • [Cites] Br J Radiol. 1997 Oct;70(838):1068-70 [9404215.001]
  • [Cites] Abdom Imaging. 2000 Nov-Dec;25(6):655-7 [11029102.001]
  • [Cites] AJR Am J Roentgenol. 2001 Oct;177(4):856 [11566688.001]
  • (PMID = 21063471.001).
  • [ISSN] 1612-3174
  • [Journal-full-title] German medical science : GMS e-journal
  • [ISO-abbreviation] Ger Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2975263
  • [Keywords] NOTNLM ; granulosa cell tumor / lipomeiomyoma / total laparoscopic hysterectomy
  •  go-up   go-down


100. Canis M, Farina M, Jardon K, Rabischong B, Rivoire C, Nohuz E, Botchorishvili R, Pouly JL, Mage G: [Laparoscopy and gynecologic cancer in 2005]. J Gynecol Obstet Biol Reprod (Paris); 2006 Apr;35(2):117-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Coelioscopie et cancer en gynécologie: le point en 2005.
  • Animal studies suggested that the risk of tumor dissemination in non traumatized peritoneum is higher after a pneumoperitoneum than after a laparotomy.
  • Changing these parameters we may, in the future, be able to create a peritoneal environment adapted to oncologic patients in order to prevent or to decrease the risks of peritoneal dissemination and/or of postoperative tumor growth.
  • In patients with endometrial cancer, the laparoscopic approach should be reserved to clinical stage I disease, if the vaginal extraction is anticipated to be easy accounting for the volume of the uterus and the local conditions.
  • In cervical cancer, the laparoscopic approach should be reserved to patients with favorable prognostic factors: stage IB of less than 2 cm in diameter.
  • Laparoscopy is the gold standard for the surgical diagnosis of adnexal masses.
  • In contrast restaging of an early ovarian cancer initially managed as a benign mass, is a good indication of the laparoscopic approach.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Laparoscopy
  • [MeSH-minor] Animals. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / epidemiology. Peritoneal Neoplasms / etiology. Pneumoperitoneum, Artificial / adverse effects. Risk Factors. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575358.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 190
  •  go-up   go-down






Advertisement